

UNIVERSITY OF THE
WITWATERSRAND,
JOHANNESBURG



MMED RESEARCH REPORT

A DESCRIPTIVE STUDY OF NEONATES BORN TO MOTHERS WITH TUBERCULOSIS IN A LOW MIDDLE INCOME COUNTRY

INVESTIGATOR: Sonia Mariza Neves da Silva MBBCh (Wits), BSc (NWU), BPsych (NWU)

STUDENT NUMBER: 0102093V

DEGREE: MMED (Paediatrics)

SUPERVISORS:

Professor Daynia Ballot

MBBCh (Wits), FCPaed (SA), PhD

Paediatric Neonatologist at Charlotte Maxeke Johannesburg Academic Hospital

Dr Tanusha Ramdin

MBBCh (Wits), FCPaed (SA), MMED, DCH Cert

Paediatric Neonatologist at Charlotte Maxeke Johannesburg Academic Hospital

20th of July 2021

Declaration

I, Sonia Mariza Neves da Silva declare that this Research Report is my own, unaided work. It is being submitted for the Degree of MMED Paediatrics at the University of the Witwatersrand, Johannesburg. It has not been submitted before for any degree or examination at any other University.



20th of July 2021

Dedication

I dedicate this work to my mother,
who has always believed in my dreams and remained a pillar of strength through it all

Acknowledgements

I would like to give heartfelt thanks to my supervisors Prof Ballot and Dr Ramdin for their guidance and unwavering support. Many thanks are also extended to the staff at Charlotte Maxeke Johannesburg Academic Hospital involved in the data collection for the neonatal unit.

Table of contents

List of figures and tables

List of abbreviations

Chapter:	i – Submissible paper	1
	ii – Author guidelines	13
	iii – Approved protocol	32
Appendix:	iv – Ethics.....	54
	v – Turnitin certificate.....	55

List of figures and tables

Figure 1: Flow diagram describing sample selection	5
Table 1: Maternal clinical and demographic characteristics.....	7
Table 2: Neonatal clinical and demographic characteristics.....	7

List of abbreviations

TB	Tuberculosis
SA	South Africa
CMJAH	Charlotte Maxeke Johannesburg Academic Hospital
HIV	Human immunodeficiency virus
ARV	Antiretroviral
VL	Viral load
CD4	Cluster of differentiation 4
EOS	Early-onset sepsis
LOS	Late-onset sepsis
RDS	Respiratory distress syndrome
CLD	Chronic lung disease
LMIC	Low middle income country
LTB	Latent tuberculosis
ATB	Active tuberculosis
MDR TB	Multidrug-resistant tuberculosis
CTB	Congenital tuberculosis
PTB	Postnatal tuberculosis
REDCap	Research electronic data capture
WITS	The University of the Witwatersrand
CXR	Chest radiograph
AFB	Acid fast bacilli
GXP	Gene Xpert
INH	Isoniazid
RIF	Rifampicin
XDR TB	Extensively drug-resistant tuberculosis
JHB	Johannesburg
BCG	Bacillus Calmette-Guérin
PCR	Polymerase chain reaction
NCPAP	Nasal continuous positive airway pressure
IPPV	Intermittent positive pressure ventilation

A Descriptive Study of Neonates born to Mothers with Tuberculosis in a low income country

SMN da Silva, MBBCh, BSc, BPsych; **T Ramdin**, MBBCh, FPaed (SA), MMED, DCH Cert; **DE Ballot**, MBBCh, FCPaed (SA), PhD.

Department of Paediatrics and Child Health, University of the Witwatersrand and Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa.

Corresponding author: SMN da Silva (soniadassilva@yahoo.com)

ABSTRACT.

Background. Tuberculosis (TB) in pregnancy is associated with unfavourable maternal and neonatal outcomes. A paucity of South African (SA) data exists regarding the impact of maternal TB on neonates.

Objectives. To describe demographical and clinical characteristics and outcomes of mothers diagnosed with TB and their neonates and compare it to TB negative mothers and their neonates.

Methods. This was a retrospective unmatched case-control study of sick and premature neonates admitted to Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) between 1 January 2013 and 31 December 2017. Cases were identified as neonates born to mothers with TB. Controls included the next two inborn neonates delivered to TB negative mothers.

Results. Maternal TB prevalence in this study was 0.9%. The majority of mothers confirmed human immunodeficiency virus (HIV) positive had TB and few were on antiretroviral (ARV) therapy. If taking ARVs, these mothers commonly defaulted treatment, had a higher viral load (VL) and a lower cluster of differentiation 4 (CD4) compared to the control group. Likewise, TB exposed neonates were more likely to be HIV positive. Mothers with TB were at higher risk for spontaneous abortions, pre-eclampsia, maternal anaemia, chorioamnionitis, pneumonia and more likely to require ventilation. Tuberculosis exposed neonates had higher rates of early-onset sepsis (EOS), late-onset sepsis (LOS), respiratory distress syndrome (RDS), chronic lung disease (CLD) and need for ventilation. The only factor associated with a high risk of TB in mothers was CD4.

Conclusion. Unfavourable neonatal and maternal outcomes associated with TB found at CMJAH were consistent with that reported globally.

Background

Tuberculosis (TB) is widely prevalent today, maintaining its status as one of the leading deadliest communicable diseases.^[1,2] Tuberculosis has evaded eradication rendering it a global public health problem with a high burden of disease.^[1-3] The incidence of TB in pregnancy is unknown but thought to be higher in low middle income countries (LMIC).^[4,5] Pregnant women diagnosed with latent TB (LTB) are more likely to progress to active TB (ATB).^[1,6] Active TB is associated with a higher incidence of unfavourable maternal outcomes such as death, chorioamnionitis, spontaneous abortion, postpartum anaemia, pre-eclampsia, pneumonia and ventilatory support.^[4-9] Tuberculosis is a common opportunistic infection present in individuals with human immunodeficiency virus (HIV).^[5] High morbidity and mortality rates are affiliated with HIV-associated TB during pregnancy.^[9-11] Pregnancy-related multidrug-resistant (MDR) TB and late initiation of anti-TB treatment have also been correlated with less favourable outcomes.^[5,6,9]

The disease burden associated with neonatal TB is difficult to quantify.^[2] Despite classifying congenital TB (CTB) as rare, a South African study reported the transmission rate of *Mycobacterium Tuberculosis* in neonates as 16%.^[2,3,5,7,10] Tuberculosis in the neonatal period is subdivided into CTB and postnatal TB (PTB).^[1] Postnatal TB is contracted within the first weeks of life from a contagious adult in the form of airborne particles.^[1,2] In comparison, CTB is acquired in utero or during delivery.^[1-3,5,7,12-14] Distinguishing between CTB and PTB for the purpose of a diagnosis can be challenging due to vague signs and symptoms.^[1,3,5]

Neonates born to mothers with ATB have a higher incidence of poor outcomes namely an increased risk of premature birth, low birth weight, intrauterine growth retardation, small for gestational age, RDS and a six-fold increase in perinatal death.^[1,4-7,9,11,15] Neonates born to mothers with TB were also more likely to have a congenital abnormality.^[6] South Africa (SA) has one of the highest-burden of TB and HIV worldwide.^[10] Multidrug-resistant TB is a persistent threat in SA as evidenced by the increasing number of cases reported.^[16,17] The impact of MDR TB and HIV on mothers and their offspring is difficult to quantify due to limited data available.^[18] Despite the high prevalence of HIV and its association with TB, there is a paucity of research on the effects of maternal TB on neonatal outcomes internationally and in SA. Our aim was to describe the outcomes of mothers diagnosed with TB and their neonates and compare it to mothers unexposed to TB and their offspring, therefore contributing to the local and regional evidence base which would enhance our understanding of the burden of TB disease in neonates.

Methods

This was a retrospective unmatched case-control study using data from the CMJAH neonatal database. The study population included sick and premature neonates born to mothers with documented TB admitted to the neonatal unit at CMJAH between 1 January 2013 and 31 December 2017. Neonates for whom files could not be retrieved, were excluded as well as infants born to mothers with unknown TB status. The control group comprised of sick and premature neonates born to mothers without TB.

Data collection

Data was collected on discharge of patients from clinician completed hospital records for the purpose of a clinical audit. Research Electronic Data Capture (REDCap) hosted by the University of the Witwatersrand (WITS) was used to capture and manage the data.^[19] Neonatal and maternal outcome to hospital discharge, obstetric information, neonatal and maternal clinical and demographic details were retrieved from the database for statistical analyses. Patients were identified from the database reviewed records.

Maternal TB was defined as a diagnosis of TB in the labour room notes as documented either by chest radiograph (CXR) or positive sputum for acid-fast bacilli (AFB) and Gene Xpert (GXP). Based on the results of the GXP, mothers were classified as either having rifampicin sensitive or resistant TB. Multidrug-resistant TB was defined as TB that did not respond to two anti-TB drugs namely isoniazid (INH) and rifampicin (RIF) as detected on GXP.^[20] Extensively drug-resistant TB (XDR TB) is resistant to INH and RIF, plus any fluoroquinolone and at least one of the three injectable second-line drugs.^[20] Respiratory distress syndrome, a disease of prematurity is characterised by a deficiency of surfactant leading to signs of respiratory distress necessitating oxygen.^[21] Chronic lung disease was defined as requiring supplemental oxygen for more than 28 days.^[22] Early-onset sepsis constituted a positive blood culture within 72 hours from birth and late-onset sepsis was defined as a positive blood culture > 72 hours after birth.

In this study, we combined the two disease entities namely CTB and PTB using the term 'perinatal TB'. Perinatal TB was defined as TB present in the first month of life as diagnosed by positive GXP obtained from the neonate or histology suggestive of TB detected in the placenta.

Study site and routine care

Charlotte Maxeke Johannesburg Academic Hospital is a quaternary hospital in Johannesburg (JHB) that functions as a referral centre for surrounding clinics and district hospitals.

Mothers suspected of TB had a CXR ordered and sputum tested for AFB and GXP done. When TB is suspected in the neonate, gastric aspirate specimens are sent for TB microscopy, culture and GXP.^[2,13,14] Gastric lavage is positive in 70% of cases and is the preferred method of testing in infants because they swallow their sputum and cannot expectorate.^[14] Ziehl-Neelsen staining, culture and histopathological examination of the placenta remains the gold standard for diagnosing CTB.^[23]

Neonates born to mothers diagnosed with TB were admitted for TB workup. For both asymptomatic and symptomatic neonates exposed to TB, no Bacillus Calmette-Guérin (BCG) vaccine was administered at birth. Gastric aspirates for AFB and TB culture was done as well as a CXR. Asymptomatic neonates were started on prophylactic INH for 3 months and reviewed at follow up clinic 3 months later. Symptomatic infants were notified and initiated on anti-TB treatment. Neonates born to mothers with MDR or XDR TB were managed on an individual basis in consultation with a paediatric infectious disease specialist. Placentas belonging to TB confirmed mothers were examined and sent off for histology.

All pregnant women who presented at CMJAH were offered an HIV test with pre and post-test counselling. Mothers testing positive for HIV were initiated on antiretroviral (ARV) therapy and had their viral loads (VL) and cluster of differentiation 4 (CD4) counts monitored. Similarly, all neonates that were born to HIV positive mothers were tested for HIV using a polymerase chain reaction (PCR) test. Neonatal HIV prophylaxis prescribed was dependent on the mother's VL and the duration of ARV therapy before delivery.^[24]

Statistical methods

Controls for this study were not matched to the study population and were taken from the database by systematically selecting the next two sick or premature inborn neonates delivered to TB negative mothers. Statistical analysis was done using SPSS Statistics (IBM) version 25. Categorical variables were described using frequencies and percentages. Continuous variables were described as means and standard deviations where data were distributed normally or median and range if skewed. Demographic and clinical characteristics for control and case groups were compared. Independent t-test was used to compare differences in means across cases and controls for normally distributed continuous variables. Pearson Chi-square or Fischer exact tests were used to determine if there was a statistically significant difference in frequency between cases and controls. A p-value of less than 0.05 was considered significant. For all variables found to be significantly different, a logistic regression model was used to calculate adjusted odds ratios for associations with TB.

Ethics

The study was approved by the Human Research Ethics Committee at WITS, JHB (Clearance Certificate No. M180614).

Results

A total of 8684 sick and premature neonates were admitted to CMJAH between 1 January 2013 and 31 of December 2017. Four hundred and twenty-one of these neonates were excluded as they were born to mothers with unknown TB results. Seventy-four files were retrieved and one file was excluded, resulting in a final case sample of 74. The control group was comprised of 148 neonates born to mothers without TB.




Figure 1. Flow diagram describing sample selection

Maternal characteristics

The following description of maternal clinical and demographical data is summarised in Table 1. The prevalence of maternal TB in this study was 0.9%, of which MDR TB accounted for 15% (11/74). Most of the TB positive mothers were initiated on first-line compared to second-line TB treatment (63/74, 85% vs 11/74, 15%) and (7/74) 10% of mothers defaulted TB treatment. The majority of mothers were initiated on TB treatment during pregnancy (47/74, 64%), followed by those started at delivery (15/74, 20%), with the minority of mothers being initiated before the pregnancy (12/74, 16%). The presence of maternal TB was found in the following sites namely pulmonary 81% (60/74), abdomen 5% (4/74), meningeal 4% (3/74), spinal 3% (2/74), cardiac 3% (2/74), thyroid 1% (1/74), lymphatic 1% (1/74) and cryptococcal 1% (1/74). Tuberculosis was not detected in any of the thirteen placentas sent for histopathological examination.

When comparing maternal clinical characteristics for cases and controls, there was no significant difference in the mode of delivery and antenatal care. The majority of mothers confirmed HIV positive were from the case group. TB negative mothers were more likely to be on ARVs than TB positive mothers. Thirty-five percent (19/55) of HIV positive mothers in the case group defaulted ARV therapy versus only 8% (3/38) in the control group. On average, mothers with TB had higher VL than the control group (111 203.38 count +/- 205 848.713 vs 488.13 +/- 1025.085) $p = 0.044$ and lower CD4 than the control group (225.51 +/- 259.863 vs 494.90 +/- 217.202) $p < 0.001$.

Results showed that mothers with TB were more likely to have pregnancy related complications including spontaneous abortion (15/74, 21% vs 12/148, 8%) $p = 0.006$, pre-eclampsia (18/74, 24% vs 17/148, 11%) $p = 0.008$, maternal anaemia (38/74, 51% vs 27/148, 18%) $p < 0.001$, chorioamnionitis (9/74, 12% vs 3/148, 2%) $p = 0.002$ and pneumonia (5/74, 7% vs 0/148, 0%) $p < 0.001$. Significantly more mothers were ventilated in the case group compared to the control group $p < 0.001$, with many mothers requiring ventilation and facemask oxygen if confirmed TB positive. The mortality for mothers with TB (6/74, 8%) was higher than that for mothers without TB (1/148, 0.5%).

Neonatal characteristics

The following description of neonatal clinical and demographical data is summarised in Table 2. Perinatal TB was not diagnosed in the neonates born to TB confirmed mothers. The incidence of HIV amongst the neonates was 3%. All of the TB exposed neonates received TB prophylaxis. There was no significant difference in the sex and neonatal HIV prophylaxis between cases and controls. Similarly no significant difference in birth weight or gestational age was found between the two groups

(2070.47 grams +/- 845.802 vs 2150.70 grams +/- 936.376)) $p = 0.523$ (34.03 weeks +/- 4.14 vs 34.39 weeks +/- 4.82) $p = 0.565$. More TB exposed neonates were confirmed HIV PCR positive than TB unexposed neonates (2/74, 3% vs 0/38, 0%) $p = 0.04$.

Tuberculosis exposed neonates commonly developed EOS and LOS more often than TB unexposed neonates. The organisms causing EOS and LOS included *C. parapsilosis*, *A. baumannii*, *C. glabrata* and *C. krusei*. Tuberculosis exposed neonates were significantly more likely to have neonatal related complications including RDS and CLD and less likely to have congenital infections and congenital abnormalities.

Fifty-nine percent of neonates were ventilated in the case group compared to the neonates in the control group with more TB exposed neonates requiring nasal continuous positive airway pressure (NCPAP) than intermittent positive pressure ventilation (IPPV). Tuberculosis exposed neonates were ventilated on average for longer than non-exposed TB neonates. Receiving postnatal steroids was not found to be significant. Neonates from both groups were admitted to hospital for a similar duration of time (15.73 +/- 16.261 vs 13.92 +/- 17.845) $p = 0.45$. No significant difference in neonatal mortality was found between the two groups ($p = 0.3$).

Table 1: Maternal clinical and demographic characteristics

Characteristics	Case n/N (%) (74)	Control n/N (%) (148)	p-value
Maternal factors:			
<u>Mode of delivery</u>			1.0
Vaginal	36/74 (49)	72/148 (48)	
Caesarean	38/74 (51)	76/148 (51)	
Antenatal Care	61/74 (82)	125/148 (84)	0.7
HIV status	55/74 (74)	38/148 (26)	<0.001
ARV	49/55 (89)	38/38 (100)	0.01
Defaulted ARV	19/55 (35)	3/38 (8)	0.02
Ventilation	11/74 (15)	1/148 (0.7)	<0.001
<u>Type of ventilation</u>			
Facemask	6/74 (8)	0/148 (0)	<0.001
Intubation	5/74 (7)	1/148 (0.5)	
Deaths	6/74 (8)	1/148 (0.7)	<0.001

Table 2: Neonatal clinical and demographic characteristics

Characteristics	Case n/N (%) (74)	Control n/N (%) (148)	p-value
Neonatal factors:			
<u>Sex</u>			
Female	36/74 (49)	67/148 (45)	0.63
Male	38/74 (51)	81/148 (55)	
HIV prophylaxis	54/55 (98)	38/38 (100)	0.3
Congenital infections	1/74 (1)	0/148 (0)	0.1
EOS	2/74 (3)	0/148 (0)	0.025
LOS	11/74 (15)	17/148 (11)	0.4
Congenital abnormalities	6/74 (8)	15/148 (10)	0.7
RDS	39/74 (53)	52/148 (35)	0.012
Ventilation	44/74 (59)	65/148 (44)	0.018
<u>Type of ventilation</u>			
NCPAP	38/74 (51)	62/148 (42)	0.04
IPPV	6/74 (8)	3/148 (2)	
CLD	9/74 (12)	8/148 (5)	0.037
Postnatal steroids	19/74 (26)	44/148 (29)	0.5
Deaths	7/74 (9)	21/148 (14)	0.3

On multivariable logistic regression, the only factor associated with a high risk of TB in mothers was CD4.

Discussion

This study shows that ATB during pregnancy is associated with poor neonatal and maternal outcomes. Mothers with TB were more likely to have a spontaneous abortion, pre-eclampsia, maternal anaemia, chorioamnionitis, pneumonia and require ventilatory support. Likewise, neonates exposed to TB had higher rates of EOS and LOS, RDS, CLD, the need for ventilatory support and a longer duration of ventilation. Despite perinatal TB being associated with a higher neonatal mortality in the literature, the mortality rate for both case and control groups in the study was similar. This could be in part due to more neonates being initiated on TB prophylaxis and that maternal TB is being diagnosed and treated earlier in pregnancy.

In our retrospective unmatched case-control study, none of the neonates born to TB positive mothers were diagnosed with perinatal TB. The prevalence of perinatal TB was therefore in keeping with the literature but significantly lower than reported in a Durban based SA study.^[2,3,5,7,10] Of note, only 13 placentas belonging to TB positive mothers were sent for TB testing. Furthermore, the placentas underwent histopathological examination alone, without TB culture testing or Ziehl-Neelsen staining.

This along with the low number of placentas submitted for testing could account for the lack of perinatal TB diagnosed.

The prevalence of TB in pregnant women in the study was 0.9%. Africa is said to have the highest case burden of TB in pregnant women and the burden is thought to be higher than that of the general population.^[3,5,17] This is as a result of many cases remaining undiagnosed due to a low threshold of suspicion and similarity of TB symptoms with the physiological symptoms of pregnancy.^[3,5,17] As a result, the prevalence of pregnancy-related TB could be higher than reported in the study.

On the grounds of a high burden of disease, the World Health Organisation (WHO) has implemented the Sustainable Development Goals with the aim of ending the global TB epidemic by 2035.^[25] To this end, despite the challenge of distinguishing between TB and the physiological symptoms of pregnancy, 64% (47/74) women diagnosed with TB were initiated on anti-TB treatment during the course of their pregnancy, highlighting physician's efforts to recognise and treat TB.

Tuberculosis rates in Africa are said to be 10 times higher in HIV positive pregnant women than in those pregnant who are HIV negative.^[18] In the study, more mothers with TB were diagnosed HIV positive than those mothers without, confirming this relationship. The late initiation of anti-TB treatment correlates with unfavourable maternal outcomes. Mothers with TB who were diagnosed HIV positive were more likely to not be on ARV treatment despite being aware of their HIV status. Once diagnosed and initiated on ARV and anti-TB treatment, mothers with TB commonly defaulted both treatments compared to the control group. As a result, TB exposed mothers with HIV had higher VL and lower CD4 counts.

Fifteen percent of TB confirmed mothers had MDR TB. Up to 20% of TB associated maternal deaths in South Africa were caused by HIV.^[6] Human immunodeficiency virus-associated TB during pregnancy coupled with the pregnancy-related MDR TB where mothers didn't seek treatment or defaulted treatment in the face of high VL and low CD4 explains the higher mortality seen in TB confirmed mothers compared to mothers without TB. Cluster of differentiation 4 was the only factor identified by multivariable logistic regression with an association to maternal TB. This can be explained by the fact that low CD4 counts act as an indicator of disease pointing to a higher likelihood of developing or acquiring TB if diagnosed HIV positive.

Limitations

Mothers with undiagnosed TB may have been missed, so the prevalence of neonatal or maternal TB cannot be accurately determined from this study. One of the neonatal records were excluded due to incompleteness which would also negatively impact our ability to confidently comment on the prevalence of neonatal TB. Placentas for TB confirmed mothers were not always sent for TB detection. Furthermore, if placentas were sent for testing, only histopathological examination was done which would impact on the reporting of prevalence of neonatal TB. The long term outcome of all neonates post-discharge was unknown. Information pertaining to the mother's TB status was obtained from the labour ward nursery notes and as a result if it is not stated that the mother was TB positive we assumed that the mother was TB negative which is a limitation as it may not reflect the true number of women presenting with TB during pregnancy to CMJAH.

Conclusion

This study showed that perinatal TB is a rare disease in SA and that high morbidity and mortality rates correspond to HIV-associated TB during pregnancy. Pregnancy-related MDR TB and late initiation of anti-TB treatment also correlated with poorer outcomes which are consistent with data published in developed countries. It also confirmed that the unfavourable neonatal and maternal outcomes associated with TB found at CMJAH were consistent with those reported globally.

References:

1. Saramba MI, Zhao D. A perspective of the diagnosis and management of congenital tuberculosis. *Journal of Pathogens*. 2016;2:1-8.
2. Skevaki CL, Kafetzis DA. Tuberculosis in neonates and infants: epidemiology, pathogenesis, clinical manifestations, diagnosis, and management issues. *Pediatric Drugs*. 2005;7:219-234.
3. Samedi V, Field SK, Al Awad E, Ratcliffe G, Yusuf K., Riedel S. Congenital tuberculosis in an extremely preterm infant conceived after in vitro fertilization: case report. *BioMedCentral Pregnancy and Childbirth*. 2017;17:1-4
4. Sugarman J, Colvin C, Moran AC, Oxlade O. Tuberculosis in pregnancy: an estimate of the global burden of disease. *Lancet Global Health*. 2014;2:710-716.
5. Loto O, Awowole I. Tuberculosis in pregnancy: a review. *Journal of Pregnancy*. 2012;2:224-230.
6. Bates M, Ahmed Y, Kapata N, Maeurer M, Mwaba P, Zumla A. Perspectives on tuberculosis in pregnancy. *International Journal of Infectious Diseases*. 2015;32:124-127.
7. Stähelin-Massik J, Carrel T, Duppenhaler A, Zeilinger G, Gnehm HE. Congenital tuberculosis in a premature infant. *Swiss Medical Weekly*. 2002;132:598-602.
8. Sobhy S, Babiker Z, Zamora J, Khan K, Kunst H. Maternal and perinatal mortality and morbidity associated with tuberculosis during pregnancy and the postpartum period: a systematic review and meta-analysis. *British Journal of Obstetrics and Gynaecology: An International Journal of Obstetrics and Gynaecology*. 2017;124:727-733.
9. Mathad JS, Gupta A. Tuberculosis in Pregnant and Postpartum Women: Epidemiology, management, and research gaps. *Clinical Infectious Diseases*. 2012;55:1532-1549.
10. Pillay T, Sturm AW, Khan M, et al. Vertical transmission of *Mycobacterium tuberculosis* in KwaZulu Natal: Impact of HIV-1 co-infection. *Int J Tuberc Lung Dis*. 2004;8:59-69.
11. Toro PL, Schneider KL, Carter RJ, Abrams EJ, El-Sadr WM, MD, Howard AA, MD, Maternal and infants outcomes with concurrent treatment of Tuberculosis and HIV in pregnant women. *Journal of Acquired Immune Deficiency Syndrome*. 2011;56:63-67.
12. Oe KO. Congenital tuberculosis : A case report and review of the literature. *BMJ*. 2012;40:93-96.
13. Mittal H, Das S, Faridi MMA. Management of newborn infant born to mother suffering from tuberculosis: Current recommendations & gaps in knowledge. *Indian J Med Res* . 2014;140:32-39.
14. Di Comite A, Esposito S, Villani A, et al. How to manage neonatal tuberculosis. *Journal of Perinatology*. 2015;36:80-85.

15. Lacourse SM, Greene SA, Dawson-Hahn EE, Hawes SE. Risk of Adverse Infant Outcomes Associated with Maternal Tuberculosis in a Low Burden Setting: A Population-Based Retrospective Cohort Study. *Infectious Diseases in Obstetrics and Gynecology*. 2016;1-8.
16. World Health Organisation. The World Health Report 2016 - Global tuberculosis report. <http://apps.who.int/medicinedocs/documents/s23098en/s23098n.pdf/> (Accessed April 2018)
17. Maningi NE, Daum LT, Rodriguez JD, et al. Multi- and Extensively-Drug Resistant *Mycobacterium tuberculosis* in South Africa: A Molecular Analysis of Historical Isolates. *Journal of Clinical Microbiology*. 2018;56:1-34.
18. Khan M, Pillay T, Moodley J, Ramjee A, Padayatchi N. Pregnancies complicated by multidrug-resistant tuberculosis and HIV co-infection in Durban, South Africa. *Int J Tuberc Lung Dis*. 2007;11:706-708.
19. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. *Journal of Biomedical Information*. 2009;42:377-381.
20. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert® Mtb/Rif assay for pulmonary tuberculosis and rifampicin resistance in adults. *Cochrane Database Syst Rev*. 2014;21:1-167.
21. Sweet DG, Carnielli V, Greisen G, et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome. *Neonatology*. 2017;111:107-125.
22. Baraldi E, Filippone M. Chronic lung disease after premature birth. *N Engl J Med*. 2007;357:1946-1955.
23. Abramowsky CR, Gutman J, Hilinski JA. *Mycobacterium tuberculosis* infection of the placenta. A study of the early (innate) inflammatory response in two cases. *Pediatric and Developmental Pathology*. 2012;15:132-136.
24. South African National Department of Health - Guideline for the Prevention of Mother to Child Transmission of Communicable Infections. https://www.nicd.ac.za/wp-content/uploads/2019/11/Guidelines-for-the-Prevention-of-Transmission-of-Communicable-Diseases-from-mother-to-child_28-October.pdf (Accessed October 2019)
25. World Health Organisation. The End TB Strategy 2015 - Global tuberculosis report. <https://www.who.int/tb/strategy.pdf/> (Accessed April 2018)

Author Guidelines: SAJCH

Please view the [Author Tutorial](#) for guidance on how to submit on Editorial Manager.

To submit a manuscript, please proceed to the SAJCH Editorial Manager website: [Editorial Manager](#)

To access and submit an article already in production, please see the guidelines [here](#).

Please take the time to familiarise yourself with the policies and processes below. If you still have any questions, please do not hesitate to ask our editorial staff (tel.: +27 (0)21 532 1281, email: submissions@hmpg.co.za).

Article Processing Charges

All articles published in the South African Journal of Child Health are open access and freely available online upon publication. This is made possible by applying a business model to offset the costs of peer review management, copyediting, design and production, by charging an article-processing charge (APC) of R3 180 (ex Vat) for all articles published. The charge applies only to Research articles submitted after 1 Jan 2019. The APC is standard and does not vary based on length, colour, figures, or other elements.

When submitting a Research article to the SAJCH, the submitting author must agree to pay the APC should the article be accepted for publication. The APC is payable when your manuscript is editorially accepted and before production commences for publication. The submitting author will be notified that payment is due and given details on the available methods of payment. Prompt payment is advised; the article will not enter into production until payment is received.

Queries can be directed to claudian@hmpg.co.za.

Please refer to the section on ‘Sponsored Supplements’ regarding the publication of supplements, where a charge is applicable. Queries can be directed to dianes@hmpg.co.za or claudian@hmpg.co.za

Authorship

Named authors must consent to publication. Authorship should be based on: (i) substantial contribution to conceptualisation, design, analysis and interpretation of data; (ii) drafting or critical revision of important scientific content; or (iii) approval of the version to be published. These conditions must all be met for an individual to be included as an author (uniform requirements for manuscripts submitted to biomedical journals; refer to www.icmje.org)

If authors' names are added or deleted after submission of an article, or the order of the names is changed, all authors must agree to this in writing.

Please note that co-authors will be requested to verify their contribution upon submission. Non-verification may lead to delays in the processing of submissions.

Author contributions should be listed/described in the manuscript.

Conflicts of interest

Conflicts of interest can derive from any kind of relationship or association that may influence authors' or reviewers' opinions about the subject matter of a paper. The existence of a conflict – whether actual, perceived or potential – does not preclude publication of an article. However, we aim to ensure that, in such cases, readers have all the information they need to enable them to make an informed assessment about a publication's message and conclusions. We require that both authors and reviewers declare all sources of support for their research, any personal or financial relationships (including honoraria, speaking fees, gifts received, etc) with relevant individuals or organisations connected to the topic of the paper, and any association with a product or subject that may constitute a real, perceived or potential conflict of interest. If you are unsure whether a specific relationship constitutes a conflict, please contact the editorial team for advice. If a conflict remains undisclosed and is later brought to the attention of the editorial team, it will be considered a serious issue prompting an investigation with the possibility of retraction.

Research ethics committee approval

Authors must provide evidence of Research Ethics Committee approval of the research where relevant. Ensure the correct, full ethics committee name and reference number is included in the manuscript.

If the study was carried out using data from provincial healthcare facilities, or required active data collection through facility visits or staff interviews, approval should be sought from the relevant provincial authorities. For South African authors, please refer to the guidelines for submission to the [National Health Research Database](#). Research involving human subjects must be conducted according to the principles outlined in the Declaration of Helsinki. Please refer to the National Department of Health's guideline on [Ethics in Health research: principles, processes and structures](#) to ensure that the appropriate requirements for conducting research have been met, and that the HPCSA's [General Ethical Guidelines for Health Researchers](#) have been adhered to.

Clinical trials

Since 1st December 2005, all clinical trials conducted in South Africa have been required to be registered in the [South African National Clinical Trials Register](#). The *SAJCH* therefore requires that clinical trials be registered in the relevant public trials registry at or before the time of first patient enrolment as a condition for publication. The trial registry name and registration number must be included in the manuscript.

Protection of rights to privacy

Patient

Information that would enable identification of individual patients should not be published in written descriptions, photographs, radiographs and pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) has given informed written consent for publication and distribution. We further recommend that the published article is disseminated not only to the involved researchers but also to the patients/participants from whom the data was drawn. Refer to [Protection of Research Participants](#). The signed consent form should be submitted with the manuscript to enable verification by the editorial team.

Other individuals

Any individual who is identifiable in an image must provide written agreement that the image may be used in that context in the *SAJCH*.

Copyright notice

Copyright remains in the Author's name. The work is licensed under a Creative Commons Attribution - Noncommercial Works License. Authors are required to complete and sign an Author Agreement form that outlines Author and Publisher rights and terms of publication. The Agreement form should be uploaded along with other submissions files and any submission will be considered incomplete without it [*forthcoming*].

Material submitted for publication in the *SAJCH* is accepted provided it has not been published or submitted for publication elsewhere. Please inform the editorial team if the main findings of your paper have been presented at a conference and published in abstract form, to avoid copyright infringement. The *SAJCH* does not hold itself responsible for statements made by the authors. The corresponding author should also indicate if the research forms part of a postgraduate short report, dissertation or thesis.

Previously published images

If an image/figure has been previously published, permission to reproduce or alter it must be obtained by the authors from the original publisher and the figure legend must give full credit to the original source. This credit should be accompanied by a letter indicating that permission to reproduce the image has been granted to the author/s. This letter should be uploaded as a supplementary file during submission.

Privacy statement

The *SAJCH* is committed to protecting the privacy of its website and submission system users. The names, personal particulars and email addresses entered in the website or submission system will not be made available to any third party without the user's permission or due process. By registering to use the website or submission system, users consent to receive communication from the *SAJCH* or its publisher HMPG on matters relating to the journal or associated publications. Queries with regard to privacy may be directed to publishing@hmpg.co.za.

Ethnic/race classification

Use of racial or ethnicity classifications in research is fraught with problems. If you choose to use a research design that involves classification of participants based on race or ethnicity, or discuss issues with reference to such classifications, please ensure that you include a detailed rationale for doing so, ensure that the categories you describe are carefully defined, and that socioeconomic, cultural and lifestyle variables that may underlie perceived racial disparities are appropriately controlled for. Please also clearly specify whether race or ethnicity is classified as reported by the patient (self-identifying) or as perceived by the investigators. Please note that it is not appropriate to use self-reported or investigator-assigned racial or ethnic categories for genetic studies.

Continuing Professional Development (CPD)

SAJCH is an HPCSA-accredited service provider of CPD materials. Principal authors can earn up to 15 CPD continuing education units (CEUs) for publishing an article; co-authors are eligible to earn up to 5 CEUs; and reviewers of articles can earn 3 CEUs. Each month, *SAJCH* also publishes a CPD-accredited questionnaire relating to the academic content of the journal. Successful completion of the questionnaire with a pass rate of 70% will earn the reader 3 CEUs. Administration of our CPD programme is managed by Medical Practice Consulting. To complete questionnaires and obtain certificates, please visit [MRP Consulting](#)

Manuscript preparation

Preparing an article for anonymous review

To ensure a fair and unbiased review process, all submissions are to include an anonymised version of the manuscript. The exceptions to this requirement are Editorials, Correspondence, Book reviews and Obituary submissions.

Submitting a manuscript that needs additional blinding can slow down your review process, so please be sure to follow these simple guidelines as much as possible:

- An anonymous version should not contain any author, affiliation or particular institutional details that will enable identification.
- Please remove title page, acknowledgements, contact details, funding grants to a named person, and any running headers of author names.

- Mask self-citations by referring to your own work in third person.

General article format/layout

Submitted manuscripts that are not in the correct format specified in these guidelines will be returned to the author(s) for correction prior to being sent for review, which will delay publication.

General:

- Manuscripts must be written in UK English (this includes spelling).
- The manuscript must be in Microsoft Word or RTF document format. Text must be 1.5 line spaced, in 12-point Times New Roman font, and contain no unnecessary formatting (such as text in boxes). Pages and lines should be numbered consecutively.
- Please make your article concise, even if it is below the word limit.
- Qualifications, **full** affiliation (department, school/faculty, institution, city, country) and contact details of ALL authors must be provided in the manuscript and in the online submission process.
- Abbreviations should be spelt out when first used and thereafter used consistently, e.g. 'intravenous (IV)' or 'Department of Health (DoH)'.
- Scientific measurements must be expressed in SI units except: blood pressure (mmHg) and haemoglobin (g/dL).
- Litres is denoted with an uppercase L e.g. 'mL' for millilitres).
- Units should be preceded by a space (except for % and °C), e.g. '40 kg' and '20 cm' but '50%' and '19°C'.
- Please be sure to insert proper symbols e.g. μ not u for micro, α not a for alpha, β not B for beta, etc.
- Numbers should be written as grouped per thousand-units, i.e. 4 000, 22 160.
- Quotes should be placed in single quotation marks: i.e. The respondent stated: '...'
- Round brackets (parentheses) should be used, as opposed to square brackets, which are reserved for denoting concentrations or insertions in direct quotes.

If you wish material to be in a box, simply indicate this in the text. You may use the table format –this is the *only* exception. Please DO NOT use fill, format lines and so on.

SAJCH is a Journal on child health, therefore for articles involving genetics, it is the responsibility of authors to apply the following:

- Please ensure that all genes are in italics, and proteins/enzymes/hormones are not.
- Ensure that all genes are presented in the correct case e.g. TP53 not Tp53.

**** NB:** Copyeditors cannot be expected to pick up and correct errors wrt the above, although they will raise queries where concerned.

- Define all genes, proteins and related shorthand terms at first mention, e.g. '188del11' can be glossed as 'an 11 bp deletion at nucleotide 188.'
- Use the latest approved gene or protein symbol as appropriate:
 - Human Gene Mapping Workshop (HGMW): genetic notations and symbols
 - HUGO Gene Nomenclature Committee: approved gene symbols and nomenclature
 - OMIM: Online Mendelian Inheritance in Man (MIM) nomenclature and instructions
 - Bennet et al. Standardized human pedigree nomenclature: Update and assessment of the recommendations of the National Society of Genetic Counselors. J Genet Counsel 2008;17:424-433: standard human pedigree nomenclature.

Preparation notes by article type

Research

Guideline word limit: 3 000 words (excluding abstract and bibliography)

Research articles describe the background, methods, results and conclusions of an original research study. The article should contain the following sections: introduction, methods, results, discussion and conclusion, and should include a structured abstract (see below). The introduction should be concise – no more than three paragraphs – on the background to the research question, and must include references to other relevant published studies that clearly lay out the rationale for conducting the study. Some common reasons for conducting a study are: to fill a gap in the literature, a logical extension of previous work, or to answer an important clinical question. If other papers related to the same study have been published previously, please make sure to refer to them specifically. Describe the study methods in as much detail as possible so that others would be able to replicate the study should they need to. Where appropriate, sample size calculations should be included to demonstrate that the study is not underpowered. Results should describe the study sample as well as the findings from

the study itself, but all interpretation of findings must be kept in the discussion section, which should consider primary outcomes first before any secondary or tertiary findings or post-hoc analyses. The conclusion should briefly summarise the main message of the paper and provide recommendations for further study.

- May include up to 6 illustrations or tables.
- A max of 20 - 25 references

Structured abstract

- This should be no more than 250 words, with the following recommended headings:
 - o **Background:** why the study is being done and how it relates to other published work.
 - o **Objectives:** what the study intends to find out
 - o **Methods:** must include study design, number of participants, description of the intervention, primary and secondary outcomes, any specific analyses that were done on the data.
 - o **Results:** first sentence must be brief population and sample description; outline the results according to the methods described. Primary outcomes must be described first, even if they are not the most significant findings of the study.
 - o **Conclusion:** must be supported by the data, include recommendations for further study/actions.
 - o Please ensure that the structured abstract is complete, accurate and clear and has been approved by all authors. It should be able to be intelligible to the reader without referral to the main body of the article.
 - o Do not include any references in the abstracts.

[Here](#) is an example of a good abstract.

Scientific letters/short reports

These include case reports, side effects of drugs and brief or negative research findings.

Guideline word limit: 1500 words

- Abstract: unstructured, of about 100-150 words
- May include only one illustration or table

- A maximum of 6 references

Editorials

Guideline word limit: 1 000 words

These opinion or comment articles are usually commissioned but we are happy to consider and peer review unsolicited editorials. Editorials should be accessible and interesting to readers without specialist knowledge of the subject under discussion and should have an element of topicality (why is a comment on this issue relevant now?) There should be a clear message to the piece, supported by evidence.

Please make clear the type of evidence that supports each key statement, e.g.:

- expert opinion
- personal clinical experience
- observational studies
- trials
- systematic reviews.

Review articles

Review articles should always be discussed with the Editor prior to submission.

Guideline word limit: 4 000 words

These are welcome, but should be either commissioned or discussed with the Editor before submission. A review article should provide a clear, up-to-date account of the topic and be aimed at non-specialist hospital doctors and general practitioners. They should be aligned to practice in South and/or sub-Saharan Africa and not a precis of reviews published in the international literature

Please ensure that your article includes:

- Abstract: unstructured, of about 100-150 words, explaining the review and why it is important
- Methods: Outline the sources and selection methods, including search strategy and keywords used for identifying references from online bibliographic databases. Discuss the quality of evidence.

- When writing: clarify the evidence you used for key statements and the strength of the evidence. Do not present statements or opinions without such evidence, or if you have to, say that there is little or no evidence and that this is opinion. Avoid specialist jargon and abbreviations, and provide advice specific to southern Africa.
- Personal details: Please supply your qualifications, position and affiliations and MP number (used for CPD points); address, telephone number and fax number, and your e-mail address; and a short personal profile (50 words) and a few words about your current fields of interest.

Correspondence (Letters to the Editor)

Guideline word limit: 400 words

Letters to the editor should relate either to a paper or article published by the SAJCH or to a topical issue of particular relevance to the journal's readership

- May include only one illustration or table
- Must include a correspondence address.

Obituaries

Guideline word limit: 400 words

Should be offered within the first year of the practitioner's death, and may be accompanied by a photograph.

Illustrations/photos/scans

- If illustrations submitted have been published elsewhere, the author(s) should provide evidence of consent to republication obtained from the copyright holder.
- Figures must be numbered in Arabic numerals and referred to in the text e.g. '(Fig. 1)'.
- Each figure must have a caption/legend: Fig. 1. Description (any abbreviations in full).
- All images must be of high enough resolution/quality for print.
- All illustrations (graphs, diagrams, charts, etc.) must be in PDF form.

- Ensure all graph axes are labelled appropriately, with a heading/description and units (as necessary) indicated. Do not include decimal places if not necessary e.g. 0; 1.0; 2.0; 3.0; 4.0 etc.
- Scans/photos showing a specific feature e.g. *Intermediate magnification micrograph of a low malignant potential (LMP) mucinous ovarian tumour. (H&E stain)*. –include an arrow to show the tumour.
- Each image must be attached individually as a 'supplementary file' upon submission (not solely embedded in the accompanying manuscript) and named Fig. 1, Fig. 2, etc.

Tables

- Tables should be constructed carefully and simply for intelligible data representation. Unnecessarily complicated tables are strongly discouraged.
- Large tables will generally not be accepted for publication in their entirety. Please consider shortening and using the text to highlight specific important sections, or offer a large table as an addendum to the publication, but available in full on request from the author.
- Embed/include each table in the manuscript Word file - do not provide separately as supplementary files.
- Number each table in Arabic numerals (Table 1, Table 2, etc.) consecutively as they are referred to in the text.
- Tables must be cell-based (i.e. not constructed with text boxes or tabs) and editable.
- Ensure each table has a concise title and column headings, and include units where necessary.
- Footnotes must be indicated with consecutive use of the following symbols: * † ‡ § ¶ || then ** †† ‡‡ etc.

Do not: Use [Enter] within a row to make ‘new rows’:

Rather:

Each row of data must have its own proper row:

Do not: use separate columns for *n* and %:

Rather:

Combine into one column, *n* (%):

Do not: have overlapping categories, e.g.:

Rather:

Use <> symbols or numbers that don't overlap:

References

NB: *Only complete, correctly formatted reference lists in Vancouver style will be accepted. If reference manager software is used, the reference list and citations in text are to be unformatted to plain text before submitting.*

- Authors must verify references from original sources.
- Citations should be inserted in the text as superscript numbers between square brackets, e.g. These regulations are endorsed by the World Health Organization,^[2] and others.^[3,4-6]
- All references should be listed at the end of the article in numerical order of appearance in the Vancouver style (not alphabetical order).
- Approved abbreviations of journal titles must be used; see the [List of Journals in Index Medicus](#).
- Names and initials of all authors should be given; if there are more than six authors, the first three names should be given followed by et al.
- Volume and issue numbers should be given.
- First and last page, in full, should be given e.g.: 1215-1217 **not** 1215-17.
- Wherever possible, references must be accompanied by a digital object identifier (DOI) link). Authors are encouraged to use the DOI lookup service offered by [CrossRef](#):
 - o On the Crossref homepage, paste the article title into the 'Metadata search' box.
 - o Look for the correct, matching article in the list of results.
 - o Click Actions > Cite
 - o Alongside 'url =' copy the URL between { }.
 - o Provide as follows, e.g.: <https://doi.org/10.7196/07294.937.98x>

Some examples:

- *Journal references:* Price NC, Jacobs NN, Roberts DA, et al. Importance of asking about glaucoma. Stat Med 1998;289(1):350-355. <http://dx.doi.org/10.1000/hgjr.182>

- *Book references:* Jeffcoate N. Principles of Gynaecology. 4th ed. London: Butterworth, 1975:96-101.
- *Chapter/section in a book:* Weinstein L, Swartz MN. Pathogenic Properties of Invading Microorganisms. In: Sodeman WA, Sodeman WA, eds. Pathologic Physiology: Mechanisms of Disease. Philadelphia: WB Saunders, 1974:457-472.
- *Internet references:* World Health Organization. The World Health Report 2002 - Reducing Risks, Promoting Healthy Life. Geneva: WHO, 2002. <http://www.who.int/whr/2002> (accessed 16 January 2010).
- Legal references
- Government Gazettes:

National Department of Health, South Africa. National Policy for Health Act, 1990 (Act No. 116 of 1990). Free primary health care services. Government Gazette No. 17507:1514. 1996.

In this example, 17507 is the Gazette Number. This is followed by :1514 - this is the notice number in this Gazette.

- Provincial Gazettes:

Gauteng Province, South Africa; Department of Agriculture, Conservation, Environment and Land Affairs. Publication of the Gauteng health care waste management draft regulations. Gauteng Provincial Gazette No. 373:3003, 2003.

- Acts:

South Africa. National Health Act No. 61 of 2003.

- Regulations to an Act:

South Africa. National Health Act of 2003. Regulations: Rendering of clinical forensic medicine services. Government Gazette No. 35099, 2012. (Published under Government Notice R176).

- Bills:

South Africa. Traditional Health Practitioners Bill, No. B66B-2003, 2006.

- Green/white papers:

South Africa. Department of Health Green Paper: National Health Insurance in South Africa. 2011.

- Case law:

Rex v Jopp and Another 1949 (4) SA 11 (N)

Rex v Jopp and Another: Name of the parties concerned

1949: Date of decision (or when the case was heard)

(4): Volume number

SA: SA Law Reports

11: Page or section number

(N): In this case Natal - where the case was heard. Similarly, (C) would indicate Cape, (G) Gauteng, and so on.

NOTE: no . after the v

- *Other references (e.g. reports) should follow the same format:* Author(s). Title. Publisher place: Publisher name, year; pages.
- Cited manuscripts that have been accepted but not yet published can be included as references followed by '(in press)'.
- Unpublished observations and personal communications in the text must **not** appear in the reference list. The full name of the source person must be provided for personal communications e.g. '... (Prof. Michael Jones, personal communication)'.

From submission to acceptance

Submission and peer-review

To submit an article:

- Please ensure that you have prepared your manuscript in line with the *SAJCH* requirements.
- All submissions should be submitted via [Editorial Manager](#)
- The following are required for your submission to be complete:

- o Anonymous manuscript (unless otherwise stated)
- o Author Agreement form [forthcoming]
- o Manuscript
- o Any supplementary files: figures, datasets, patient consent form, permissions for published images, etc.
- o Once the submission has been successfully processed on Editorial Manager, it will undergo a technical check by the Editorial Office before it will be assigned to an editor who will handle the review process. If the author guidelines have not been appropriately followed, the manuscript may be sent back to the author for correcting.

Peer Review Process

All manuscripts are reviewed initially by the Editor-in-Chief and only those that meet the scientific and editorial standards of the journal, and fit within the aims and scope of the journal, will be sent for external peer review. Each manuscript is reviewed by either one or two reviewers selected on the basis of their expertise in the field. A double blind review process is followed at SAJCH.

Authors are expected to receive feedback from reviewers and an editorial decision within approximately 6 weeks of submission. The time period of the entire review process may vary however depending upon the quality of the manuscript submitted, reviewers' responses and the time taken by the authors to submit the revised manuscript.

Manuscripts from review may be accepted, rejected or returned to the author for revision or resubmission for review. Authors will be directed to submit revised manuscripts within two months of receiving the editor's decision, and are requested to submit a point by point response to the reviewers' comments. Manuscripts which authors are requested to revise and resubmit will be sent for a second round of peer review, often to the original set of reviewers. All final decisions on a manuscript are at the Editor's discretion.

Production process

1. An accepted manuscript is passed to a Managing Editor to assign to a copyeditor (CE).

2. The CE copyedits in Word, working on house style, format, spelling/grammar/punctuation, sense and consistency, and preparation for typesetting.
3. If the CE has an author queries, he/she will contact the corresponding author and send them the copyedited Word doc, asking them to solve the queries by means of track changes or comment boxes.
4. The authors are typically asked to respond within 1-3 days. Any comments/changes must be clearly indicated e.g. by means of track changes. Do not work in the original manuscript - work in the copyedited file sent to you and make your changes clear.
5. The CE will finalise the article and then it will be typeset.
6. Once typeset, the CE will send a PDF of the file to the authors to complete their final check, while simultaneously sending to the 2nd-eye proof reader.
7. The authors are typically asked to complete their final check and sign-off within 1-2 days. No major additional changes can be accommodated at this point.
8. The CE implements the authors' and proof reader's mark-ups, finalises the file, and prepares it for the upcoming issue.

Changing contact details or authorship

Please notify the Editorial Department of any contact detail changes, including email, to facilitate communication.

Errata and retractions

Errata

Should you become aware of an error or inaccuracy in yours or someone else's contribution after it has been published, please inform us as soon as possible via an email to publishing@hmpg.co.za, including the following details:

- Journal, volume and issue in which published
- Article title and authors
- Description of error and details of where it appears in the published article
- Full detail of proposed correction and rationale

We will investigate the issue and provide feedback. If appropriate, we will correct the web version immediately, and will publish an erratum in the next issue. All investigations will be conducted in accordance with guidelines provided by the Committee on Publication Ethics ([COPE](#)).

Retractions

Retraction of an article is the prerogative of either the original authors or the editorial team of HMPG. Should you wish to withdraw your article before publication, we need a signed statement from all the authors.

Should you wish to retract your published article, all authors have to agree in writing before publication of the retraction.

Send an email to publishing@hmpg.co.za, including the following details:

- Journal, volume and issue to which article was submitted/in which article was published
- Article title and authors
- Description of reason for withdrawal/retraction.

We will make a decision on a case-by-case basis upon review by the editorial committee in line with international best practices. Comprehensive feedback will be communicated with the authors with regard to the process. In case where there is any suspected fraud or professional misconduct, we will follow due process as recommended by the Committee on Publication Ethics (COPE), and in liaison with any relevant institutions.

When a retraction is published, it will be linked to the original article.

Indexing

Published articles are covered by the following major indexing services. As such articles published in the *SAJCH* are immediately available to all users of these databases, guaranteed a global and African audience:

- DOAJ
- AIM
- AJOL
- Crossref

- Sabinet
- Scielo
- EBSCO
- EMBASE

Sponsored supplements

Contact claudian@hmpg.co.za for information on submitting ad hoc/commissioned supplements, including guidelines, conference/congress abstracts, Festschrifts, etc.

Submission Preparation Checklist

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.

1. Named authors consent to publication and meet the requirements of authorship as set out by the journal.
2. The submission has not been previously published, nor is it before another journal for consideration.
3. The text complies with the stylistic and bibliographic requirements in [Author Guidelines](#).
4. The manuscript is in Microsoft Word or RTF document format. The text is single-spaced, in 12-point Times New Roman font, and contains no unnecessary formatting.
5. Illustrations/figures are high resolution/quality (not compressed) and in an acceptable format (preferably TIFF or PNG). These must be submitted as 'supplementary files' (not in the manuscript).
6. For illustrations/figures or tables that have been published elsewhere, the author has obtained written consent to republication from the copyright holder.
7. Where possible, references are accompanied by a digital object identifier (DOI) and PubMed ID (PMID)/PubMed Central ID (PMCID).
8. An abstract has been included where applicable.
9. The research was approved by a Research Ethics Committee (if applicable)
10. Any conflict of interest (or competing interests) is indicated by the author(s).

Copyright Notice

Copyright of published material remains in the Authors' name. This allows authors to use their work for their own non-commercial purposes without seeking permission from the Publisher, subject to properly acknowledging the Journal as the original place of publication.

Authors are free to copy, print and distribute their articles, in full or in part, for teaching activities, and to deposit or include their work in their own personal or institutional database or on-line website. Authors are requested to inform the Journal/Publishers of their desire/intention to include their work in a thesis or dissertation or to republish their work in any derivative form (but not for commercial use).

Material submitted for publication in the *SAJCH* is accepted provided it has not been published or submitted for publication elsewhere. Please inform the editorial team if the main findings of your paper have been presented at a conference and published in abstract form, to avoid copyright infringement.

Privacy Statement

The *SAJCH* is committed to protecting the privacy of the users of this journal website. The names, personal particulars and email addresses entered in this website will be used only for the stated purposes of this journal and will not be made available to third parties without the user's permission or due process. Users consent to receive communication from the *SAJCH* for the stated purposes of the journal. Queries with regard to privacy may be directed to publishing@hmpg.co.za.

MMED RESEARCH PROPOSAL

April 2018

A DESCRIPTIVE STUDY OF NEONATES BORN TO MOTHERS WITH TUBERCULOSIS IN A LOW MIDDLE-INCOME COUNTRY

INVESTIGATOR: Sonia Mariza Neves da Silva MBBCH (Wits), BSc (NWU), BPsych (NWU)

STUDENT NUMBER: 0102093V

DEGREE: MMED (Paediatrics)

SUPERVISORS:

Professor Daynia Ballot

MBBCH (Wits), FCPaed (SA), PhD

Paediatric Neonatologist at Charlotte Maxeke Johannesburg Academic Hospital

Dr Tanusha Ramdin

MBBCH (Wits), FCPaed (SA), MMED, DCH Cert

Paediatric Neonatologist at Charlotte Maxeke Johannesburg Academic Hospital

OUTLINE	PG No
Introduction	35
Objectives	38
Methods	38
Data analysis	40
Ethical considerations	41
Time lines	41
Funding.....	41
Limitations.....	42
Reference list	42
Appendix A.....	45

GLOSSARY OF TERMS

TB	Tuberculosis
WW	World war
HIV	Human immunodeficiency virus
AIDS	Acquired immunodeficiency syndrome
WHO	World health organisation
PDA	Patent ductus arteriosus
CMJAH	Charlotte Maxeke Johannesburg Academic Hospital
REDCap	Research Electronic data capture
VON	Vermont Oxford Network

INTRODUCTION

Tuberculosis (TB) is widely prevalent today despite being a disease of antiquity.¹ Scientific documentation of TB dates back to as early as 8000 BC.^{1,2} TB has plagued human history for millennia as evidenced by its presence in the bony remains of ancient Egyptian mummies to its affliction of soldiers in World War (WW)1 and WW2.^{1,2} Tuberculosis has maintained the status as one of the leading deadliest communicable diseases, ranking ninth above human immunodeficiency virus (HIV) / acquired immunodeficiency syndrome (AIDS).^{3,4} It has evaded eradication despite medical advances rendering it a largely curable and preventable disease.^{2,5} Tuberculosis is, therefore a global public health problem that has resulted from the scientific, medical, social and political failures in society.² On the grounds of a high burden of disease the World Health Organisation (WHO) has implemented the Sustainable Development Goals with the aim of ending the global TB epidemic by 2035.^{3,6}

According to the WHO, in 2016 there were approximately 10.4 million new cases of TB of which 3.7 million were women and 1 million were children with the majority of these cases occurring in Asia and Africa.⁶ Women of childbearing age (15-45) carry seventy-five percent of the TB burden and the prevalence of TB in pregnant women is thought to be higher than that of the general population.^{7,8} This has a crippling effect on socio-economic development as it disempowers women therefore encouraging the cycle of poverty.⁷ It is estimated that active TB affects 216 500 pregnant women globally.¹⁴ Africa is said to have the highest case burden of TB in pregnant women at around 41.3% but many cases remain undiagnosed due to a low threshold of suspicion and similarity of TB symptoms with physiological symptoms of pregnancy.^{5,7,12} As a result, the full extent of the burden of disease amongst pregnant women is unknown but it is expected to be higher than currently reported especially in developing countries.^{7,8}

Pregnant and postpartum women are at an increased risk for contracting TB due to the physiologic, hormonal, and immunologic changes that occur during pregnancy.^{11,12} The physiological immunosuppression associated with pregnancy, resulting in a dampened T-helper 1 pro-inflammatory response may mask disease symptoms leaving these women susceptible to new mycobacterial infection or reactivation of TB.^{4,13,14,15} Women diagnosed with latent pattern TB in pregnancy are more likely to progress to an active pattern TB.^{4,13} Active TB during pregnancy is known to have unfavourable maternal and infant outcomes.^{13,16}

In 2013, 1.5 million people worldwide died from TB of which 510 000 were women, one-third of these women were co-infected with HIV and roughly 15–35% of these deaths occurred during pregnancy.^{9,13,14,17} Tuberculosis is the third leading cause of death worldwide among women of child-bearing age.^{6,7,9,12,13} It is one of the most common opportunistic infections present in individuals with HIV.⁷ There is a 16-27 times higher risk of developing TB if diagnosed HIV positive.⁶ Human immunodeficiency virus-associated TB is linked to higher morbidity and mortality rates during pregnancy and postpartum.^{15,19} Over 50% of the TB associated maternal mortality in pregnancy is due to coinfection with HIV, therefore maternal mortality is increased in women who are co-infected with HIV and TB.^{7,13} Up to 20% of TB associated maternal deaths in South Africa were caused by HIV.¹⁶ Pregnancy-associated multidrug-resistant (MDR) TB and late initiation of anti-TB treatment have even less favourable outcomes.^{7,13,14} Other poor maternal outcomes documented in women diagnosed with TB include chorioamnionitis, spontaneous abortion, postpartum anaemia, vaginal bleeding, preeclampsia, the need for transfusions, pneumonia and mechanical ventilation.^{7,9,14}

The disease burden associated with neonatal TB is difficult to accurately quantify.¹⁸ Although around 350 cases of congenital TB have been reported in the literature classifying it as a rare infection, the prevalence in a Durban based South African study was estimated to be around 16% TB.^{5,19} Tuberculosis in the neonatal period can be subdivided into two types: congenital and postnatally acquired TB.⁴

Postnatally acquired TB, which is more common, differs from congenital TB in that the infant is often infected after birth by a contagious adult (mother or undiagnosed family member) suffering from pulmonary TB.^{4,18} These neonates acquire TB within the first weeks of life from adults harbouring *M. tuberculosis* which is transmitted by respiratory aerosol to them in the form of infective airborne particles called droplet nuclei.¹⁷

Neonates contract congenital TB caused by the bacterium *M. tuberculosis* either in utero through the haematogenous placental transmission of the organism via the umbilical vein from the mother to the liver of the foetus, at delivery via the ingestion or aspiration of infected amniotic fluid or by direct contact with an infected birth canal during delivery.^{4,20,21,22} The liver and lungs are commonly affected with a primary focus developing in the liver and tubercle bacilli infecting the lungs.^{10,18,21,22} Congenital TB can be distinguished from postnatal TB based on Cantwell's revision of Beitzki's criteria which includes the presence of a primary hepatic complex/ caseating granuloma on percutaneous liver biopsy at birth, TB infection of the

placenta or maternal genital tract TB, and the demonstration of lesions during the first week of life.^{5,16,18,20,,21}

It can become challenging to differentiate congenital TB from other neonatal or congenital infections due to nonspecific signs and symptoms like hepatosplenomegaly, respiratory distress, fever, lymphadenopathy, abdominal distension, lethargy, irritability, ear discharge, and papular skin lesions which result in the gross underreporting of the disease.^{4,7,16,17,19,21} Tuberculosis is known to mimic common premature conditions such as chronic lung disease, patent ductus arteriosus (PDA), pneumonia and sepsis.¹⁶ Most infected neonates are asymptomatic at birth with many manifesting TB around 2-3 weeks of age although some develop symptoms of congenital TB during the first days of life.²² Distinguishing clinically between congenital and postnatally acquired TB in order to make a diagnosis can be difficult as signs and symptoms may be vague.^{4,5} For the purpose of this study, we are going to combine the two disease entities using the term 'perinatal TB'. If perinatal TB is suspected gastric aspirate specimens can be obtained from the neonate for TB microscopy and culture.^{17,21,22} Gastric lavage is positive in 70% of case and is the preferred method in infants who swallow their sputum and cannot expectorate.²² The Ziehl-Neelsen staining together with histopathological examination of the placenta remains the gold standard for diagnosing TB.²³

Neonates born to mothers with active TB have a higher incidence of poor outcomes.¹³ These include a nine-fold increased risk of premature birth, low birth weight, intrauterine growth retardation, small for gestational age, respiratory distress syndrome and a six-fold increase in perinatal death.^{4,7,9,12,13,14} Babies born to mothers with TB were more likely to have a congenital abnormality.⁸ The mortality rate due to perinatal TB is nearly 50% which is as a result of delayed diagnosis and treatment.⁴

South Africa is one of the countries with the highest burden of TB and HIV.¹⁹ Multidrug-resistant TB is a persistent threat in South Africa.²⁴ There is an increasing number of multidrug-resistant cases of TB reported in South Africa.^{6,24} The impact of multidrug-resistant TB and HIV in mothers and their offspring is difficult to quantify due to limited data available.²⁵ Despite the high prevalence of HIV and its association with TB, there is a paucity of information on the impact of maternal TB on neonates in South Africa. The aim of this study is to describe the maternal and neonatal characteristics of infants presenting at Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) who were born to mothers with TB.

OBJECTIVES

OBJECTIVES

- To describe the demographic and clinical characteristics, as well as the short term outcomes of the neonates with or without TB born to mothers with TB
- To compare the two group of neonates born to mothers with or without TB
- To document the number of neonates with perinatal TB
- To describe the demographic and clinic characteristics of mothers with TB.

METHOD

STUDY DESIGN

This study is a retrospective case-control record review of neonates presenting to CMJAH between 1 January 2013 and 31 December 2017 born to mothers with TB. Cases will be classified as neonates born to mothers with TB, a control group will be comprised of neonates born to mothers without TB.

SITE OF STUDY

The study will be conducted in the neonatal section of the Paediatric department at CMJAH in Parktown, Gauteng Province.

STUDY POPULATION

The study population will include all neonatal patients with or without TB born to mothers with documented TB who were admitted within 72 hours of birth to CMJAH between 1 January 2013 and 31 December 2017. The sample size will be made up of 75 neonates born to mother with TB and 75 neonates born to mothers without TB.

INCLUSION CRITERIA

Cases: All neonates born to mothers with TB.

Controls: All the next consecutive inborn neonates born to mothers without TB.

EXCLUSION CRITERIA

Neonates for whom files could not be retrieved or are lost will be excluded from the study.

Neonates born to mothers with undocumented TB status will be excluded.

DEFINITIONS

Maternal TB is defined as a diagnosis of TB in the labour room notes.

Perinatal TB is defined as TB present in the first month of life as diagnosed by positive TB GeneXpert on gastric washing or histology of placenta.

CMJAH NEONATAL UNIT

The CMJAH neonatal unit consists of 14 ventilator beds, 35 high care, 30 low care and 10 kangaroo mother care beds. All neonates below 1750 grams are admitted to the neonatal unit. Neonates who are exposed to TB are admitted and investigated by the neonatal staff. These neonates are notified and followed up by the District clinical specialist team.

In all cases of maternal TB, the placenta is sent for histology and culture and gastric washings are sent from the neonates for acid-fast bacilli and GeneXpert. All TB exposed neonates who are admitted to the neonatal unit are treated with prophylactic INH. Neonates born to mothers with MDR or XDR TB are managed on an individual basis in consultation with an infectious diseases specialist.

DATA VARIABLES

The following maternal and neonatal variables will be looked at:

Maternal demographics and characteristics: antenatal care, HIV status: positive or negative, chorioamnionitis, type of ventilatory support and duration, pneumonia, postpartum anaemia, outcome: died or survived, spontaneous abortion, preeclampsia, whether treated for TB or not and time of initiation of treatment.

Neonatal demographics and characteristics:

- Gestational age, birth weight and head circumference
- Sex
- Mode of delivery
- Outcome: died or survived and duration of admission
- Whether or not diagnosed with perinatal TB
- HIV status: exposed or PCR positive/ negative
- Presence of congenital infections, indicating the type
- Early and late-onset sepsis
- Presence of congenital abnormalities, indicating the type based on the system involved

- Ventilatory support including type and duration
- Respiratory distress syndrome
- Chronic lung disease (supplementary oxygen at 28 days chronological and at 36 weeks post-conceptional age)
- Use of postnatal steroids
- TB prophylaxis given

PROCEDURES

Data on admitted neonates will be extracted from the existing CMJAH neonatal database in paediatric department. This data which is part of a continuing clinical audit is collected from clinician-completed hospital records. Data is managed using Research Electronic Data Capture (REDCap), hosted by the University of the Witwatersrand.²⁶ Definitions in the database are derived from the Vermont Oxford Network (VON) (www.vtoxford.org). The data collected for this database is rigorously checked and verified before being entered electronically. A data sheet with the relevant variables to be captured for this study will be attached (appendix A). Additional information, such as TB treatment will be obtained from retrieving hospital records.

DATA ANALYSIS

Data will be described using standard statistical methods. Categorical variables will be described using frequencies and percentages and continuous variables as means and standard deviations where data is distributed normally or median range if skewed. The two groups of neonates (TB exposed and TB unexposed) will be compared. Independent t-test or Mann-Whitney u-test will be used to compare differences in means across cases and controls for normally distributed continuous variables. Pearson chi-square tests will be used to determine if there is a statistically significant difference in frequency between cases and controls. A p-value of less than 0.05 will be considered significant. For all variables found to be significantly different, a univariant analysis will be entered into a logistic regression model to calculate adjusted odds ratios.

ETHICS

The protocol will be submitted for approval to the Human Research Ethics Committee (medical) of the University of the Witwatersrand. Permission to conduct the study will be requested from the department of paediatrics and the Chief Executive officer at CMJAH.

As this is a retrospective study, a waiver for informed consent will be requested. The Neonatal Database REDCap is confidential and has limited accessibility as it is password protected. No identifiable demographics like name, surname, hospital number or date of birth will be used. Study numbers will be allocated to the patients as a means to create anonymity and ensure confidentiality which will only be available to the student and supervisors.

TIME LINES

	April 2018	May 2018	June 2018	July 2018	Aug 2018	Sept 2018	Oct 2018	Nov 2018	Dec 2018
Literature review									
Protocol write up									
Protocol submission									
Ethical clearance									
Post grad committee clearance									
Data collection									
Data analysis and write up									

FUNDING

An estimated R300 will be required to fund the cost of stationary, binding and printing related to the study which will be borne by the investigator.

LIMITATIONS

Due to the retrospective nature of this study, records and data may be incomplete and information limited by what was previously captured which may affect the data set and weaken the result obtained. Undiagnosed mothers with TB may be missed, so the prevalence of

neonatal or maternal TB cannot be determined from this study. The long term outcome of neonates post discharge will be unknown. The information pertaining to the mother's TB status is obtained from the labour ward nursery notes and as a result if it is not stated that the mother is TB positive we assume that the mother is TB negative which is a limitation as it may not reflect the true number of women presenting with TB in pregnancy.

REFERENCE LIST

1. Frith J. History of Tuberculosis. Part 1 – Phthisis, consumption and the white plague. *Journal of Military and Veterans' Health*. 2014;22:29-35.
2. Boire NA, Riedel VAA, Parrish NM, Riedel S. Tuberculosis: From an untreatable disease in antiquity to an untreatable disease in modern times. *Journal of Ancient Disease and Preventative Remedies*. 2013;1:1-11.
3. WHO Report 2016. Global strategy and targets for tuberculosis prevention, care and control after 2015. http://apps.who.int/gb/ebwha/pdf_files/EB134/B134_12-en.pdf/
4. Saramba MI, Zhao D. A perspective of the diagnosis and management of congenital tuberculosis. *Journal of Pathogens*. 2016;2016:1-8.
5. Samedi V, Field SK, Al Awad E, Ratcliffe G, Yusuf K., Riedel S. Congenital tuberculosis in an extremely preterm infant conceived after in vitro fertilization: case report. *BioMedCentral Pregnancy and Childbirth*. 2017;17:1-4.
6. WHO Report 2016. Global tuberculosis report. <http://apps.who.int/medicinedocs/documents/s23098en/s23098n.pdf/>
7. Loto O, Awowole I. Tuberculosis in pregnancy: a review. *Journal of Pregnancy*. 2012;2:224-230.
8. El-Messidi A, Czuzoj-Shulman N, Spence AR, Abenhaim HA. Medical and obstetric outcomes among pregnant women with tuberculosis: a population-based study of 7.8 million births. *American Journal of Obstetrics and Gynecology*. 2016;215:797.
9. Sugarman J, Colvin C, Moran AC, Oxlade O. Tuberculosis in pregnancy: an estimate of the global burden of disease. *Lancet Global Health*. 2014;2:710-716.
10. Bjerkedal T, Bahna SL, Lehmann EH. Course and outcome of pregnancy in women with

- pulmonary tuberculosis. *Scandinavian Journal of Respiratory Diseases*. 1975;56:245-250.
11. Jana N, Vasishta K, Jindal SK, Khunnu B, Ghosh K. Perinatal outcome in pregnancies complicated by pulmonary tuberculosis. *International Journal of Gynaecology & Obstetrics*. 1994;44:119-124.
 12. Lacourse SM, Greene SA, Dawson-Hahn EE, Hawes SE. Risk of Adverse Infant Outcomes Associated with Maternal Tuberculosis in a Low Burden Setting: A Population-Based Retrospective Cohort Study. *Infectious Diseases in Obstetrics and Gynecology*. 2016;2016:1-8.
 13. Bates M, Ahmed Y, Kapata N, Maeurer M, Mwaba P, Zumla A. Perspectives on tuberculosis in pregnancy. *International Journal of Infectious Diseases*. 2015;32:124-127.
 14. Sobhy S, Babiker Z, Zamora J, Khan K, Kunst H. Maternal and perinatal mortality and morbidity associated with tuberculosis during pregnancy and the postpartum period: a systematic review and meta-analysis. *British Journal of Obstetrics and Gynaecology: An International Journal of Obstetrics and Gynaecology*. 2017;124:727-733.
 15. Mathad JS, Gupta A. Tuberculosis in Pregnant and Postpartum Women: Epidemiology, management, and research gaps. *Clinical Infectious Diseases*. 2012;55:1532-1549.
 16. Stähelin-Massik J, Carrel T, Duppenenthaler A, Zeilinger G, Gnehm HE. Congenital tuberculosis in a premature infant. *Swiss Medical Weekly*. 2002;132:598-602.
 17. Toro PL, Schneider KL, Carter RJ, Abrams EJ, El-Sadr WM, MD, Howard AA, MD, Maternal and infants outcomes with concurrent treatment of Tuberculosis and HIV in pregnant women. *Journal of Acquired Immune Deficiency Syndrome*. 2011;56:63-67.
 18. Skevaki CL, Kafetzis DA. Tuberculosis in neonates and infants: epidemiology, pathogenesis, clinical manifestations, diagnosis, and management issues. *Pediatric Drugs*. 2005;7:219-234.
 19. Pillay T, Sturm AW, Khan M, Adhikari M, Moodley J, Connolly C, Moodley D, Padayatchi N, Ramjee A, Coovadia HM, Sullivan JL. Vertical transmission of Mycobacterium tuberculosis in KwaZulu Natal: Impact of HIV-1 co-infection. *International Journal of Tuberculosis and Lung Diseases*. 2004;8:59-69.
 20. Oe KO. Congenital tuberculosis : A case report and review of the literature. *British Medical Journal*. 2012;40:93-6.

21. Mittal H, Das S, Faridi MMA. Management of newborn infant born to mother suffering from tuberculosis: Current recommendations & gaps in knowledge. *Indian Journal of Medical Research*. 2014;140:32-39.
22. Di Comite A, Esposito S, Villani A, Stronati M, Principi N, Bosis S, et al. How to manage neonatal tuberculosis. *Journal of Perinatology*. 2015;36:80-85.
23. Abramowsky CR, Gutman J, Hilinski JA. Mycobacterium tuberculosis infection of the placenta. A study of the early (innate) inflammatory response in two cases. *Pediatric and Developmental Pathology*. 2012;15:132-136.
24. Maningi NE, Daum LT, Rodriguez JD, Said HM, Peters RPH, Osei Sekyere J, Fischer GW, Chambers JP, Fourie PB. Multi- and Extensively-Drug Resistant Mycobacterium tuberculosis in South Africa: A Molecular Analysis of Historical Isolates. *Journal of Clinical Microbiology*. 2018;56:1-34.
25. Khan M, Pillay T, Moodley J, Ramjee A, Padayatchi N. Pregnancies complicated by multidrug-resistant tuberculosis and HIV co-infection in Durban, South Africa. *The International Journal of Tuberculosis and Lung Disease*. 2007;11:706-708.
26. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. *Journal of Biomedical Information*. 2009;42:377-81.

Appendix A

DATASHEET

STUDY NUMBER			
Gestational age			
Birthweight			
Sex	M	F	
Mode of delivery	Normal vaginal	Caesarian section	
Maternal Data			
Antenatal care	Yes	No	Unknown
HIV status	Positive	Negative	Unknown
If HIV positive:	VL:	CD4:	
ARV treatment	Yes	No	Unknown
Defaulted ARV treatment	Yes	No	Unknown
Spontaneous abortions	Yes	No	Unknown
Preeclampsia	Yes	No	Unknown
Postpartum anaemia	Yes	No	Unknown
Chorioamnionitis	Yes	No	Unknown
Ventilatory support	Yes	No	Unknown
If yes:	Type:	Duration:	
Pneumonia	Yes	No	Unknown
Diagnosed with TB	Yes	No	Unknown
Type of TB diagnosed			
TB treatment	Yes	No	Unknown
Time to initiation of treatment			

TB treatment type	First line	MDR TB	XDR TB
Defaulted TB treatment	Yes	No	Unknown
Outcome	Demised	Survived	
Neonatal Data			
Perinatal TB	Yes	No	
Placenta tested for TB	Yes	No	
If yes, result:	Positive	Negative	Unknown
HIV status	Positive	Negative	Unknown
Received HIV prophylaxis	Yes	No	Unknown
Congenital infections	Yes	No	Unknown
Early-onset sepsis	Yes	No	Unknown
If yes, organism isolated:			
Late-onset sepsis	Yes	No	Unknown
If yes, organism isolated:			
Congenital abnormalities	Yes	No	Unknown
If yes, system involved:			
RDS	Yes	No	Unknown
Chronic lung disease	Yes	No	Unknown
Use of postnatal steroids	Yes	No	Unknown
Ventilatory support	Type:	Duration:	
Duration of admission			
TB prophylaxis	Yes	No	Unknown
Outcome	Survived	Demised	



R14/49 Dr Sonia Mariza Neves da Silva et al

HUMAN RESEARCH ETHICS COMMITTEE (MEDICAL)

CLEARANCE CERTIFICATE NO. M180614

NAME: Dr Sonia Mariza Neves da Silva et al
(Principal Investigator)
DEPARTMENT: Paediatrics
Charlotte Maxeke Johannesburg Academic Hospital
Neonatal department

PROJECT TITLE: A descriptive study of neonates born to mothers with
Tuberculosis in a middle income country

DATE CONSIDERED: 29/06/2018

DECISION: Approved unconditionally

CONDITIONS:

SUPERVISOR: Prof Daynia Ballot

APPROVED BY: 
Professor CB Penny, Chairperson, HREC (Medical)

DATE OF APPROVAL: 04/09/2018

This clearance certificate is valid for 5 years from date of approval. Extension may be applied for.

DECLARATION OF INVESTIGATORS

To be completed in duplicate and **ONE COPY** returned to the Research Office Secretary on the Third Floor, Faculty of Health Sciences, Phillip Tobias Building, 29 Princess of Wales Terrace, Parktown, 2193, University of the Witwatersrand. I/we fully understand the conditions under which I am/we are authorized to carry out the above-mentioned research and I/we undertake to ensure compliance with these conditions. Should any departure be contemplated, from the research protocol as approved, I/we undertake to resubmit the application to the Committee. **I agree to submit a yearly progress report.** The date for annual re-certification will be one year after the date of convened meeting where the study was initially reviewed. In this case, the study was initially reviewed in **June** and will therefore be due in the month of **June** each year. Unreported changes to the application may invalidate the clearance given by the HREC (Medical).


Principal Investigator Signature

Date

04/09/2018

PLEASE QUOTE THE PROTOCOL NUMBER IN ALL ENQUIRIES

00820433:MMED_RESEARCH_ REPORT_Nov_2020.docx

by Daynia Ballot

Submission date: 13-Nov-2020 09:30AM (UTC+0200)

Submission ID: 1444783044

File name: f-2c21-47c5-93a5-591a217bce42_MMED_RESEARCH_REPORT_Nov_2020.docx (437.74K)

Word count: 4351

Character count: 24515

UNIVERSITY OF THE
WITWATERSRAND,
JOHANNESBURG



MMED RESEARCH REPORT

A DESCRIPTIVE STUDY OF NEONATES BORN TO MOTHERS WITH TUBERCULOSIS IN A LOW MIDDLE INCOME COUNTRY

INVESTIGATOR: Sonia Mariza Neves da Silva MBBCh (Wits), BSc (NWU), BPsych
(NWU)

STUDENT NUMBER: 0102093V

DEGREE: MMED (Paediatrics)

SUPERVISORS:

Professor Daynia Ballot
MBBCh (Wits), FCPaed (SA), PhD
Paediatric Neonatologist at Charlotte Maxeke Johannesburg Academic Hospital

Dr Tanusha Ramdin
MBBCh (Wits), FCPaed (SA), MMED, DCH Cert
Paediatric Neonatologist at Charlotte Maxeke Johannesburg Academic Hospital

Declaration

I, Sonia Mariza Neves da Silva ¹ declare that this Research Report is my own, unaided work. It is being submitted for the Degree of MMED Paediatrics at the University of the Witwatersrand, Johannesburg. It has not been submitted before for any degree or examination at any other University.

A handwritten signature in black ink, consisting of a series of loops and strokes, positioned above a horizontal line.

Acknowledgements

2

I would like to give a heartfelt thanks to my supervisors Prof Ballot and Dr Rindin for their guidance and unwavering support. Many thanks is also extended to the staff at Charlotte Maxeke Johannesburg Academic Hospital involved in the data collection for the neonatal unit.

Dedication

I dedicate this work to my mother,
who has always believed in my dreams and remained a pillar of strength through it all

Table of contents

List of figures and tables

List of abbreviations

Chapter: 1 Submissible paper

2 Author guidelines

3 Approved protocol

Appendix: 1 Ethics

2 Turnitin certificate

List of figures and tables

Figure 1: Flow diagram describing sample selection

13

Table 1: Maternal clinical and demographic characteristics

13

Table 2: Neonatal clinical and demographic characteristics

List of abbreviations

TB	Tuberculosis
SA	South Africa
¹ CMJAH	Charlotte Maxeke Johannesburg Academic Hospital
HIV	Human immunodeficiency virus
ARV	Anti-retroviral
VL	Viral load
CD4	Cluster of differentiation 4
²² EOS	Early onset sepsis
LOS	Late onset sepsis
RDS	Respiratory distress syndrome
CLD	Chronic lung disease ¹⁵
LMIC	Low middle income country
LTB	Latent tuberculosis
ATB	Active tuberculosis
MDR TB	Multidrug resistant tuberculosis
CTB	Congenital tuberculosis
PTB	Postnatal tuberculosis
¹ REDCap	Research electronic data capture
WITS	The University of the Witwatersrand
CXR	Chest radiograph
GXP	Gene Xpert
INH	Isoniazid
XDR TB	Extensively drug resistant tuberculosis
JHB	Johannesburg
²¹ AFB	Acid fast bacilli
BCG	Bacillus Calmette-Guérin
PCR	Polymerase chain reaction
²⁵ NCPAP	Nasal continuous positive airway pressure
IPPV	Intermittent positive pressure ventilation

A Descriptive Study of Neonates born to Mothers with Tuberculosis in a low income country

SMN da Silva, MBBCh, BSc, BPsych; T Ramdin, MBBCh, FPaed (SA), MMED, DCH Cert; DE Ballot, MBBCh, FCPaed (SA), PhD.

Department of Paediatrics and Child Health, University of the Witwatersrand and Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa.

Corresponding author: SMN da Silva (soniadassilva@yahoo.com)

ABSTRACT.

Background. Tuberculosis (TB) in pregnancy is associated with unfavourable maternal and neonatal outcomes. A paucity of South African (SA) data exists regarding the impact of maternal TB on neonates.

Objectives. To describe demographical and clinical characteristics and outcomes of mothers diagnosed with TB and their neonates and compare it to TB negative mothers and their neonates.

Methods. This was a retrospective unmatched case-control study of neonates admitted to Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) between 1 January 2013 and 31 December 2017. Cases were identified as neonates born to mothers with TB. Controls included the next two inborn neonates delivered to TB negative mothers.

Results. Maternal TB prevalence in this study was 0.9%. Majority of mothers confirmed human immunodeficiency virus (HIV) positive had TB and few were on anti-retroviral (ARV) therapy. If taking ARVs, these mothers commonly defaulted treatment, had higher viral load (VL) and lower cluster of differentiation 4 (CD4) compared to the control group. Likewise TB exposed neonates were more likely to be HIV positive. Mothers with TB were at higher risk for spontaneous abortions, pre-eclampsia, maternal anaemia, chorioamnionitis, pneumonia and more likely to require ventilation. Tuberculosis exposed neonates had higher rates of early onset sepsis (EOS), late onset sepsis (LOS), respiratory distress syndrome (RDS), chronic lung disease (CLD) and need for ventilation. The only factor associated with a high risk of TB in mothers was CD4.

Conclusion. Unfavourable neonatal and maternal outcomes associated with TB found at CMJAH were consistent with that reported globally.

Background

Tuberculosis is widely prevalent today, maintaining its status as one of the leading deadliest communicable diseases.^[1,2] Tuberculosis has evaded eradication rendering it a global public health problem with a high burden of disease.^[1,2,3]

The incidence of TB in pregnancy is unknown but thought to be higher in low middle income countries (LMIC).^[4,5] Pregnant women diagnosed with latent TB (LTB) are more likely to progress to active TB (ATB).^[1,7] In SA, 11 and 49 percent of pregnant women had ATB and LTB respectively.^[10] Active TB is associated with a higher incidence of unfavourable maternal outcomes such as death, chorioamnionitis, spontaneous abortion, postpartum anaemia, pre-eclampsia, pneumonia and ventilatory support.^[4,5,7,8,9] Tuberculosis is a common opportunistic infection present in individuals with HIV.^[5] High morbidity and mortality rates are affiliated with HIV-associated TB during pregnancy.^[10,11] Pregnancy related multidrug resistant (MDR) TB and late initiation of anti-TB treatment has also been correlated with less favourable outcomes.^[5,7,9]

The disease burden associated with neonatal TB is difficult to quantify.^[2] Despite classifying congenital TB (CTB) as rare, a South African study reported the transmission rate of *Mycobacterium Tuberculosis* in neonates as 16%.^[2,3,5,7,8,11] Tuberculosis in the neonatal period is subdivided into CTB and postnatal TB (PTB).^[1] Postnatal TB is contracted within the first weeks of life from a contagious adult in the form of airborne particles.^[1,11,12] In comparison, CTB is acquired in utero or during delivery.^[1,13,14,15] Distinguishing between CTB and PTB for the purpose of a diagnosis can be challenging due to vague signs and symptoms.^[1,2]

Neonates born to mothers with ATB have a higher incidence of poor outcomes namely an increased risk of premature birth, low birth weight, intrauterine growth retardation, small for gestational age, RDS and a six-fold increase in perinatal death.^[1,4,5,7,9,17] Neonates born to mothers with TB were also more likely to have a congenital abnormality.^[5]

South Africa has one of the highest burden of TB and HIV worldwide.^[11] Multidrug resistant TB is a persistent threat in SA as evidenced by the increasing number of cases reported.^[18,19] The impact of MDR TB and HIV on mothers and their offspring is difficult to quantify due to limited data available.^[20] Despite the high prevalence of HIV and its association with TB, there is a paucity of research on the effects of maternal TB on neonatal outcomes internationally and in SA. Our aim was to describe the outcomes of mothers diagnosed with TB and their neonates and compare it to mothers unexposed to TB and their offspring, therefore contributing to the local and regional evidence base which would enhance our understanding of the burden of TB disease in neonates.

Methods

This was a retrospective unmatched case-control study using data from the CMJAH neonatal database. The study population included neonates born to mothers with documented TB admitted to the neonatal unit at CMJAH between 1 January 2011 and 31 December 2017. Neonates for whom files could not be retrieved, were excluded as well as infants born to mothers with unknown TB status. The control group comprised of neonates born to mothers without TB.

Data collection

Data was collected on discharge of patients from clinician completed hospital records for the purpose of a clinical audit. Research Electronic Data Capture (REDCap) hosted by the University of the Witwatersrand (WITS) was used to capture and manage the data.^[21] Neonatal and maternal outcome to hospital discharge, obstetric information, neonatal and maternal clinical and demographic details were retrieved from the database for statistical analyses. Patients were identified from the database reviewed records.

Maternal TB was defined as a diagnosis of TB in the labour room notes as documented either by chest radiograph (CXR) or positive sputum for acid fast bacilli and Gene Xpert (GX[®]). Based on the results of the GXP, mothers were classified as either having rifampicin sensitive or resistant TB. Multidrug resistant TB was defined as TB that did not respond to two anti-TB drugs namely isoniazid (INH) and rifampicin as detected on GXP.^[22] Extensively drug resistant TB (XDR TB) is resistant to INH and rifampicin, plus any fluoroquinolone and at least one of the three injectable second-line drugs.^[22] Respiratory distress syndrome, a disease of prematurity is characterised by a deficiency of surfactant leading to signs of respiratory distress necessitating oxygen.^[23] Chronic lung disease was defined as requiring supplemental oxygen for more than 28 days.^[24] Early onset sepsis constituted a positive blood culture within 72 hours from birth and late onset sepsis was defined as a positive blood culture > 72 hours after birth.

In this study, we combined the two disease entities namely CTB and PTB using the term 'perinatal TB'. Perinatal TB was defined as TB present in the first month of life as diagnosed by positive GXP obtained from the neonate or histology suggestive of TB detected in the placenta.

Study site and routine care

Charlotte Maxeke Johannesburg Academic Hospital is a quaternary hospital in Johannesburg (JHB) that functions as a referral centre for surrounding clinics and district hospitals.

Mothers suspected of TB had a CXR ordered and sputum tested for acid fast bacilli (AFB) and GXP. When TB is suspected in the neonate, gastric aspirate specimens are sent for TB microscopy, culture and GXP.^[12,14,15] Gastric lavage is positive in 70% of case and is the preferred method of testing in infants because they swallow their sputum and cannot expectorate.^[15] Ziehl-Neelsen staining, culture and histopathological examination of the placenta remains the gold standard for diagnosing CTB.^[16] Neonates born to mothers diagnosed with TB were admitted for TB workup. For both asymptomatic and symptomatic neonates exposed to TB, no Bacillus Calmette-Guérin (BCG) vaccine was administered at birth. Gastric aspirates for AFB and TB culture was done as well as a CXR. Asymptomatic neonates were started on prophylactic INH for 3 months and reviewed at follow up clinic 3 months later. Symptomatic infants were notified and initiated on anti-TB treatment. Neonates born to mothers with MDR or XDR TB were managed on an individual basis in consultation with a paediatric infectious disease specialist. Placentas belonging to TB confirmed mothers were examined and sent off for histology.

All pregnant women who presented at CMJAH were offered an HIV test with pre and post-test counselling. Mothers testing positive for HIV were initiated on ARV therapy and had their VL and CD4 counts monitored. Similarly all neonates that were born to HIV positive mothers were tested for HIV using polymerase chain reaction (PCR) test. Neonatal HIV prophylaxis prescribed was dependent on the mother's VL and duration of ARV therapy before delivery.^[25]

Statistical methods

Controls for this study were not matched to the study population and were taken from the database by systematically selecting the next two inborn neonates delivered to TB negative mothers. Statistical analysis was done using SPSS Statistics (IBM) version 25. Categorical variables were described using frequencies and percentages. Continuous variables were described as means and standard deviations where data was distributed normally or median and range if skewed. Demographic and clinical characteristics for control and case groups were compared. Independent t-test was used to compare differences in means across cases and controls for normally distributed continuous variables. Pearson Chi-square or Fischer exact tests were used to determine if there was a statistically significant difference in frequency between cases and controls. A p-value less than 0.05 was considered significant. For all variables found to be significantly different, a logistic regression model was used to calculate adjusted odds ratios for associations with TB.

Ethics

The study was approved by the Human Research Ethics Committee at WITS, JHB (Clearance certificate No. M180614).

Results

A total of 8684 neonates were admitted to CMJAH between 1 January 2013 and 31 of December 2017. Four hundred and twenty one of these neonates were excluded as they were born to mothers with unknown TB results. Seventy four files were retrieved and one file was excluded due to incomplete data. The control group was comprised of 148 neonates born to mothers without TB.




Figure 1. Flow diagram describing sample selection

Maternal characteristics

The prevalence of maternal TB in this study was 0.9%, of which MDR TB accounted for 15% (11/74). Most of the TB positive mothers were initiated on first line compared to second line TB treatment (63/74, 85% vs 11/74, 15%) and (7/74) 10% of mothers defaulted TB treatment. The majority of mothers were initiated on TB treatment during pregnancy (47/74, 64%), followed by those started at delivery (15/74, 20%), with the minority of mothers being initiated before the pregnancy (12/74, 16%). The presence of maternal TB was found in the following sites namely pulmonary 81% (60/74), abdomen 5% (4/74), meningeal 4% (3/74), spinal 3% (2/74), cardiac 3% (2/74), thyroid 1% (1/74), lymphatic 1% (1/74) and cryptococcal 1% (1/74). Tuberculosis was not detected in any of the thirteen placentas sent for histopathological examination.

When comparing maternal clinical characteristics for cases and controls, there was no significant difference in the mode of delivery and antenatal care. The majority of mothers confirmed HIV positive were from the case group. TB negative mothers were more likely to be on ARVs than TB positive mothers. Thirty five percent (19/55) of HIV positive mothers in the case group defaulted ARV therapy versus only 8% (3/38) in the control group. On average, mothers with TB had higher VL than the control group (111 203.38 count +/- 205 848.713 vs 488.13 +/- 1025.085) $p = 0.044$ and lower CD4 than the control group (3225.51 +/- 259.863 vs 494.90 +/- 217.202) $p < 0.001$.

Results showed that mothers with TB were more likely to have pregnancy related complications including spontaneous abortion (15/74, 21% vs 12/148, 8%) $p = 0.006$, pre-eclampsia (18/74, 24% vs 17/148, 11%) $p = 0.008$, maternal anaemia (38/74, 51% vs 27/148, 18%) $p = 0.00$, chorioamnionitis (9/74, 12% vs 3/148, 2%) $p = 0.02$ and pneumonia (5/74, 7% vs 0/148, 0%) $p = 0.00$. Significantly more mothers were ventilated in the case group compared to the control group $p = 0.00$, with many mothers requiring ventilation and facemask oxygen if confirmed TB positive as shown in Table 1. The mortality for mothers with TB (6/74, 8%) was higher than that for mothers without TB (1/148, 0.5%).

Neonatal characteristics

Perinatal TB was not diagnosed in the neonates born to TB confirmed mothers. The incidence of HIV amongst the neonates was 0.03%. All of the TB exposed neonates received TB prophylaxis. There was no significant difference in the sex and neonatal HIV prophylaxis between cases and controls. Similarly no significant difference in birth weight or gestational age was found between the two groups (2070.47 grams +/- 845.802 vs 2150.70 grams +/- 936.376) $p = 0.523$ (34.03 weeks +/- 4.14 vs 34.39 weeks +/- 4.82) $p = 0.565$.

More TB exposed neonates were confirmed HIV PCR positive than TB unexposed neonates (2/74, 3% vs 0/38, 0%) $p = 0.04$. TB exposed neonates commonly developed EOS and LOS more often than TB unexposed neonates. The organisms causing EOS and LOS included *Candida parapsilosis*, *Acinebactor baumannii*, *Candida glabrata*, *Candida krusei* and Coagulase negative staphylococcus. TB exposed neonates were significantly more likely to have neonatal related complications including RDS and CLD and less likely to have congenital infections and congenital abnormalities.

Fifty nine percent of neonates were ventilated in the case group compared to the neonates in the control group with more TB exposed neonates requiring nasal continuous positive airway pressure (NCPAP) than intermittent positive pressure ventilation (IPPV). TB exposed neonates were ventilated on average for longer than non-exposed TB neonates. Receiving postnatal steroids was not found to be significant. Neonates from both groups were admitted to hospital for a similar duration of time (15.73 +/- 16.261 vs 13.92 +/- 17.845) $p = 0.45$. No significant difference in neonatal mortality was found between the two groups ($p = 0.3$).

Table 1: Maternal clinical and demographic characteristics

Characteristics	Case n/N (%) (74)	Control n/N (%) (148)	p-value
Maternal factors:			
Mode of delivery			
Vaginal	36/74 (48)	72/148 (48)	1.0
Caesarean	38/74 (51)	76/148 (51)	
Antenatal Care	61/74 (82)	125/148 (84)	0.7
HIV status	55/74 (74)	38/148 (26)	<0.001
ARV	49/55 (89)	38/38 (100)	0.01
Defaulted ARV	19/55 (34)	3/38 (8)	0.02
Ventilation	11/74 (15)	2/148 (1)	<0.001
Type of ventilation			
Facemask	6/74 (8)	0/148 (0)	<0.001
Intubation	5/74 (7)	1/148 (0.5)	
Deaths	6/74 (8)	1/148 (0.5)	0.001

Table 2: Neonatal clinical and demographic characteristics

Neonatal factors:			
Sex			
Female	36/74 (48)	67/148 (45)	0.63
Male	38/74 (52)	81/148 (55)	
HIV prophylaxis	54/55 (98)	38/38 (100)	0.3
Congenital infections	1/74 (1)	0/148 (0)	0.1
EOS	2/74 (3)	0/148 (0)	0.025
LOS	11/74 (15)	17/148 (11)	0.4
Congenital abnormalities	6/74 (8)	15/148 (10)	0.7
RDS	39/74 (53)	52/148 (35)	0.012
Ventilation	44/74 (59)	65/148 (44)	0.018
Type of ventilation			
NCPAP	38/74 (86)	87/148 (58)	<0.001
IPPV	6/74 (14)	62/148 (42)	
CLD	9/74 (7)	8/148 (5)	0.037
Postnatal steroids	19/74 (26)	44/148 (29)	0.5
Deaths	7/74 (9)	21/148 (14)	0.3

On multivariable logistic regression, the only factor associated with a high risk of TB in mothers was CD4 (OR: 4.635; 95% CI: 0.995 – 1.00).

Discussion

This study shows that ATB during pregnancy is associated with poor neonatal and maternal outcomes. Mothers with TB were more likely to have a spontaneous abortions, pre-eclampsia, maternal anaemia, chorioamnionitis, pneumonia and require ventilatory support. Likewise neonates exposed to TB had higher rates of EOS and LOS, RDS, CLD, the need for ventilatory support and a longer duration of ventilation. Despite perinatal TB being associated with a higher neonatal mortality in the literature, the mortality rate for both case and control group in the study was similar. This could be in part due to

more neonates being initiated on TB prophylaxis and that maternal TB is being diagnosed and treated earlier in pregnancy.

In our retrospective unmatched case-control study, none of the neonates born to TB positive mothers were diagnosed with perinatal TB. The prevalence of perinatal TB was therefore in keeping with the literature but significantly lower than reported in a Durban based SA study. Of note, only 13 placentas belonging to TB positive mothers were sent for TB testing. Furthermore, the placentas underwent histopathological examination alone, without TB culture testing or Ziehl-Neelsen staining. This along with the low number of placentas submitted for testing could account for the lack of perinatal TB diagnosed.

³⁷ The prevalence of TB in pregnant women in the study³² was 0.9%. Africa is said to have the highest case burden of TB in pregnant women and the burden is thought to be higher than that of the general population.^[3,5,17] This is as a result of many cases remaining undiagnosed due to a low threshold of suspicion and similarity of TB symptoms with the physiological symptoms of pregnancy.^[3,5,17] As a result, the prevalence of pregnancy related TB could actually be higher than reported in the study. On the grounds of a high burden of disease, the World Health Organisation (WHO) has implemented the Sustainable Development Goals with the aim of ending the global TB epidemic by 2035. To this end, despite the challenge of distinguishing between TB and the physiological symptoms of pregnancy, 64% (47/74) women diagnosed with TB were initiated on anti-TB treatment during the course of their pregnancy, highlighting physician's efforts to recognise and treat TB.

³⁶ Tuberculosis rates in Africa are said to be 10 times higher in HIV positive pregnant women than in those pregnant who are HIV negative.^[18] In the study more mothers with TB were diagnosed HIV positive than those mothers without, confirming this relationship. The late initiation of anti-TB treatment correlates with unfavourable maternal outcomes. Mothers with TB who were diagnosed HIV positive were more likely to not be on ARV treatment despite being aware of their HIV status. Once diagnosed and initiated on ARV and anti-TB treatment, mothers with TB commonly defaulted both treatments compared to the control group. As a result, TB exposed mothers with HIV had higher VL and lower CD4 counts.

Fifteen percent of TB confirmed mothers had MDR TB. Up to 20% of TB associated maternal deaths in South Africa were caused by HIV.^[8] Human immunodeficiency virus associated TB during pregnancy coupled with the pregnancy related MDR TB where mothers didn't seek treatment or defaulted treatment in the face of high VL and low CD4 explains the higher mortality seen in TB confirmed mothers compared to mothers without TB. Cluster of differentiation 4 was the only factor identified by multivariable logistic regression with an association to maternal TB. This can be explained by the fact that a low CD4 counts acts as an indicator of disease pointing to a higher likelihood of developing or acquiring TB if diagnosed HIV positive.

Limitations

Mothers with undiagnosed TB may have been missed, so the prevalence of neonatal or maternal TB cannot be accurately determined from this study. One of the neonatal records were excluded due to incompleteness which would also negatively impact our ability to confidently comment on the prevalence of neonatal TB. Placentas for TB confirmed mothers were not always sent for TB detection. Furthermore if placentas were sent for testing, only histopathological examination was done which would impact on the reporting of prevalence of neonatal TB. The long term outcome of all neonates post discharge was unknown. Information pertaining to the mother's TB status was obtained from the

labour ward nursery notes and as a result if it is not stated that the mother was TB positive we assumed that the mother was TB negative which is a limitation as it may not reflect the true number of women presenting with TB during pregnancy to CMJAH

Conclusion

This study showed that perinatal TB is a rare disease in SA and that high morbidity and mortality rates correspond to HIV-associated TB during pregnancy. Pregnancy related MDR TB and late initiation of anti-TB treatment also correlated with poorer outcomes which is consistent with data published in developed countries. It also confirmed that the unfavourable neonatal and maternal outcomes associated with TB found at CMJAH were consistent with that reported globally.

14. Mittal H, Das S, Faridi MMA. Management of newborn infant born to mother suffering from tuberculosis: Current recommendations & gaps in knowledge. *Indian Journal of Medical Research*. 2014;140:32-39.
15. Di Comite A, Esposito S, Villani A, Stronati M, Principi N, Bosis S, et al. How to manage neonatal tuberculosis. *Journal of Perinatology*. 2015;36:80-85.
16. Abramowsky CR, Gutman J, Hilinski JA. Mycobacterium tuberculosis infection of the placenta. A study of the early (innate) inflammatory response in two cases. *Pediatric and Developmental Pathology*. 2012;15:132-136.
17. Lacourse SM, Greene SA, Dawson-Hahn EE, Hawes SE. Risk of Adverse Infant Outcomes Associated with Maternal Tuberculosis in a Low Burden Setting: A Population-Based Retrospective Cohort Study. *Infectious Diseases in Obstetrics and Gynecology*. 2016;1-8.
18. World Health Organisation. The World Health Report 2016 - Global tuberculosis report. <http://apps.who.int/medicinedocs/documents/s23098en/s23098n.pdf/> (accessed April 2018)
19. Maningi NE, Daum LT, Rodriguez JD, Said HM, Peters RPH, Osei Sekyere J, Fischer GW, Chambers JP, Fourie PB. Multi- and Extensively-Drug Resistant Mycobacterium tuberculosis in South Africa: A Molecular Analysis of Historical Isolates. *Journal of Clinical Microbiology*. 2018;56:1-34.
20. Khan M, Pillay T, Moodley J, Ramjee A, Padayatchi N. Pregnancies complicated by multidrug-resistant tuberculosis and HIV co-infection in Durban, South Africa. *The International Journal of Tuberculosis and Lung Disease*. 2007;11:706-708.
21. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. *Journal of Biomedical Information*. 2009;42:377-381.
22. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert® Mtb/Rif assay for pulmonary tuberculosis and rifampicin resistance in adults. *Cochrane Database Syst Rev*. 2014;21:1-167.
23. Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R, Saugstad OD, Simeoni U, Speer CP, Vento M, Visser GHA, Halliday HL. European Consensus Guidelines on the Management of Respiratory Distress Syndrome. *Neonatology* 2017;111:107-125.
24. Baraldi E, Filippone M. Chronic lung disease after premature birth. *New England Journal of Medicine*. 2007;357:1946-1955.
25. South African National Department of Health - Guideline for the Prevention of Mother to Child Transmission of Communicable Infections. https://www.nicd.ac.za/wp-content/uploads/2019/11/Guidelines-for-the-Prevention-of-Transmission-of-Communicable-Diseases-from-mother-to-child_28-October.pdf (Accessed October 2019)

References:

1. Saramba MI, Zhao D. A perspective of the diagnosis and management of congenital tuberculosis. *Journal of Pathogens*. 2016;2:1-8.
2. Skevaki CL, Kafetzis DA. Tuberculosis in neonates and infants: epidemiology, pathogenesis, clinical manifestations, diagnosis, and management issues. *Pediatric Drugs*. 2005;7:219-234.
3. Samedí V, Field SK, Al Awad E, Ratcliffe G, Yusuf K., Riedel S. Congenital tuberculosis in an extremely preterm infant conceived after in vitro fertilization: case report. *BioMedCentral Pregnancy and Childbirth*. 2017;17:1-4
4. Sugarman J, Colvin C, Moran AC, Oxlade O. Tuberculosis in pregnancy: an estimate of the global burden of disease. *Lancet Global Health*. 2014;2:710-716.
5. Loto O, Awowole I. Tuberculosis in pregnancy: a review. *Journal of Pregnancy*. 2012;2:224-230.
6. El-Messidi A, Czuzoj-Shulman N, Spence AR, Abenhaim HA. Medical and obstetric outcomes among pregnant women with tuberculosis: a population-based study of 7.8 million births. *American Journal of Obstetrics and Gynecology*. 2016;215:797.
7. Bates M, Ahmed Y, Kapata N, Maeurer M, Mwaba P, Zumla A. Perspectives on tuberculosis in pregnancy. *International Journal of Infectious Diseases*. 2015;32:124-127.
8. Stähelin-Massik J, Carrel T, Duppenhaler A, Zeilinger G, Gnehm HE. Congenital tuberculosis in a premature infant. *Swiss Medical Weekly*. 2002;132:598-602.
9. Sobhy S, Babiker Z, Zamora J, Khan K, Kunst H. Maternal and perinatal mortality and morbidity associated with tuberculosis during pregnancy and the postpartum period: a systematic review and meta-analysis. *British Journal of Obstetrics and Gynaecology: An International Journal of Obstetrics and Gynaecology*. 2017;124:727-733.
10. Mathad JS, Gupta A. Tuberculosis in Pregnant and Postpartum Women: Epidemiology, management, and research gaps. *Clinical Infectious Diseases*. 2012;55:1532-1549.
11. Pillay T, Sturm AW, Khan M, Adhikari M, Moodley J, Connolly C, Moodley D, Padayatchi N, Ramjee A, Coovadia HM, Sullivan JL. Vertical transmission of *Mycobacterium tuberculosis* in KwaZulu Natal: Impact of HIV-1 co-infection. *International Journal of Tuberculosis and Lung Diseases*. 2004;8:59-69.
12. Toro PL, Schneider KL, Carter RJ, Abrams EJ, El-Sadr WM, MD, Howard AA, MD, Maternal and infants outcomes with concurrent treatment of Tuberculosis and HIV in pregnant women. *Journal of Acquired Immune Deficiency Syndrome*. 2011;56:63-67.
13. Oe KO. Congenital tuberculosis : A case report and review of the literature. *British Medical Journal*. 2012;40:93-96.

19%

SIMILARITY INDEX

14%

INTERNET SOURCES

13%

PUBLICATIONS

7%

STUDENT PAPERS

PRIMARY SOURCES

1**hdl.handle.net**

Internet Source

5%**2****Submitted to University of Witwatersrand**

Student Paper

1%**3****M. Adhikari. "Tuberculosis and tuberculosis/HIV co-infection in pregnancy", Seminars in Fetal and Neonatal Medicine, 2009**

Publication

1%**4****worldwidescience.org**

Internet Source

1%**5****Submitted to University of Strathclyde**

Student Paper

1%**6****Marian G. Michaels, Pablo Sanchez, P. Ling Lin. "Congenital Toxoplasmosis, Syphilis, Malaria, and Tuberculosis", Elsevier BV, 2018**

Publication

<1%**7****digital.lib.washington.edu**

Internet Source

<1%**bmcoralhealth.biomedcentral.com**

8

Internet Source

<1 %

9

link.springer.com

Internet Source

<1 %

10

sajch.org.za

Internet Source

<1 %

11

M. Loveday, S. Hlangu, J. Furin. "Breastfeeding in women living with tuberculosis", The International Journal of Tuberculosis and Lung Disease, 2020

Publication

<1 %

12

Kefyalew Addis Alene, Alemken Jegnie, Akilew Awoke Adane. "Multidrug-resistant tuberculosis during pregnancy and adverse birth outcomes: a systematic review and meta-analysis", BJOG: An International Journal of Obstetrics & Gynaecology, 2020

Publication

<1 %

13

Cheryl Anne Mackay, James Stephanus Smit, Farhaad Khan, Fazana Dessai, Catherine Connolly, Refiloe Masekela. "Umbilical cord interleukin-6 predicts outcome in very low birthweight infants in a high HIV-burden setting: a prospective cohort study", Archives of Disease in Childhood, 2020

Publication

<1 %

14	Submitted to De Montfort University Student Paper	<1 %
15	Submitted to University of Edinburgh Student Paper	<1 %
16	etheses.bham.ac.uk Internet Source	<1 %
17	A Ghoor, G Scher, D E Ballot. "Prevalence of and risk factors for cranial ultrasound abnormalities in very-low-birth-weight infants at Charlotte Maxeke Johannesburg Academic Hospital", South African Journal of Child Health, 2017 Publication	<1 %
18	wellbeingofwomen.com Internet Source	<1 %
19	Submitted to University of Cape Town Student Paper	<1 %
20	www.sajch.org.za Internet Source	<1 %
21	escholarship.org Internet Source	<1 %
22	mafiadoc.com Internet Source	<1 %
23	www.ajol.info Internet Source	<1 %

24	insights.ovid.com Internet Source	<1 %
25	D. Köhler, B. Schönhofer. "Sauerstofflangzeittherapie und Heimbeatmung bei chronischem Cor pulmonale", Der Internist, 1999 Publication	<1 %
26	www.pcori.org Internet Source	<1 %
27	bmcpediatr.biomedcentral.com Internet Source	<1 %
28	www.nichd.nih.gov Internet Source	<1 %
29	wwwnc.cdc.gov Internet Source	<1 %
30	Emre Baser, Istemi Han Celik, Melek Bilge, Taner Kasapoglu et al. " Abnormal Umbilical Artery Doppler is Utilized for Fetuses with Intrauterine Growth Restriction Birth at 28 –33 Gestational Weeks ", Fetal and Pediatric Pathology, 2020 Publication	<1 %
31	www.science.gov Internet Source	<1 %

32

es.scribd.com

Internet Source

<1 %

33

eprints.staffs.ac.uk

Internet Source

<1 %

34

"15th Congress of the International Pediatric Nephrology Association", Pediatric Nephrology, 2010

Publication

<1 %

35

www.ncbi.nlm.nih.gov

Internet Source

<1 %

36

M. Alexander, A. Gupta, J. S. Mathad. "Is there a connection between gestational diabetes mellitus, human immunodeficiency virus infection, and tuberculosis?", The International Journal of Tuberculosis and Lung Disease, 2019

Publication

<1 %

37

journals.plos.org

Internet Source

<1 %

38

dro.dur.ac.uk

Internet Source

<1 %

39

Emma Kalk, Alexa Heekes, Ushma Mehta, Renee de Waal et al. "Safety and Effectiveness of Isoniazid Preventive Therapy in HIV-Positive Pregnant Women on Art: An Observational

<1 %

Study using Linked Population Data", Clinical Infectious Diseases, 2020

Publication

40

Tulin Askun, Gulendam Tumen, Fatih Satil, Seyma Modanlioglu, Onur Yalci. "Chapter 6 Antimycobacterial Activity Some Different Lamiaceae Plant Extracts Containing Flavonoids and Other Phenolic Compounds", IntechOpen, 2012

Publication

<1%

41

Steingart, Karen R, Ian Schiller, David J Horne, Madhukar Pai, Catharina C Boehme, Nandini Dendukuri, and Karen R Steingart. "Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults", Cochrane Database of Systematic Reviews, 2014.

Publication

<1%

Exclude quotes On

Exclude matches < 5 words

Exclude bibliography On